0001078782-12-002687.txt : 20121022 0001078782-12-002687.hdr.sgml : 20121022 20121019173857 ACCESSION NUMBER: 0001078782-12-002687 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120831 FILED AS OF DATE: 20121022 DATE AS OF CHANGE: 20121019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMA INVESTING NEWS, INC. CENTRAL INDEX KEY: 0001520047 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 320337695 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-54738 FILM NUMBER: 121153362 BUSINESS ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 BUSINESS PHONE: 702-664-6555 MAIL ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 10-Q/A 1 f10q083112_10qz.htm AUGUST 31, 2012 10-Q/A August 31, 2012 10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 


FORM 10-Q/A

Amendment No. 1


 

  X  . QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended August 31, 2012


      . TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

For the transition period from ______ to _______


Commission File Number 000-54738


PHARMA INVESTING NEWS, INC.

[f10q083112_10qz002.gif]

(Exact name of registrant as specified in its charter)

 

Nevada

 

32-0337695

(State of incorporation)

  

(I.R.S. Employer Identification No.)

 

1810 East Sahara Ave

Suite 1571

Las Vegas, NV 89104

(Address of principal executive offices)

(702) 664-6555

(Registrant’s telephone number)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  X  . No      .

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes      . No  X  .


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer

      .

Accelerated filer

      .

Non-accelerated filer

      . (Do not check if a smaller reporting company)

Smaller reporting company

  X .



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes      . No  X  .


As of October 15, 2012, there were 5,361,015 shares of the registrant’s $0.001 par value common stock issued and outstanding.






EXPLANATORY NOTE


The purpose of this Amendment No. 1 to the Quarterly Report of Pharma Investing News, Inc. (the “Company”) on Form 10-Q for the quarterly period ended August 31, 2012, filed with the Securities and Exchange Commission on October 15, 2012, (the “Form 10-Q”), is to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T.  Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).


Other than the aforementioned, no other changes have been made to the Form 10-Q.  This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.


Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.








ITEM 6.

EXHIBITS


Exhibit

Number

Description of Exhibit

Filing

3.01

Articles of Incorporation

Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.

3.02

Bylaws

Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.

10.01

Promissory Note between the Company and Robert Lawrence Dated April 18, 2011

Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.

10.02

Joint Venture Agreement between the Company and Healthcare Media Dated July 22, 2011

Filed with the SEC on July 27, 2011 as part of our Amended Registration Statement on Form S-1/A.

10.03

Promissory Note between the Company and Robert Lawrence Dated August 25, 2011

Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.

10.04

Promissory Note between the Company and Robert Lawrence Dated August 26, 2011

Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.

14.01

Code of Ethics

Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.

31.01

Certification of Principal Executive Officer Pursuant to Rule 13a-14

Filed herewith.

31.02

Certification of Principal Financial Officer Pursuant to Rule 13a-14

Filed herewith.

32.01

CEO and CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act

Filed herewith.

101.INS*

XBRL Instance Document

Filed herewith.

101.SCH*

XBRL Taxonomy Extension Schema Document

Filed herewith.

101.CAL*

XBRL Taxonomy Extension Calculation Linkbase Document

Filed herewith.

101.LAB*

XBRL Taxonomy Extension Labels Linkbase Document

Filed herewith.

101.PRE*

XBRL Taxonomy Extension Presentation Linkbase Document

Filed herewith.

101.DEF*

XBRL Taxonomy Extension Definition Linkbase Document

Filed herewith.


*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.







SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 

 

 

  

  

PHARMA INVESTING NEWS, INC.


Dated:     October 19, 2012

 


/s/ Robert Lawrence

  

By:

ROBERT LAWRENCE

  

Its:

President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary and Treasurer


In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated.



Dated:     October 19, 2012


/s/ Robert Lawrence

  

By:  Robert Lawrence

Its:  Director




EX-31.1 2 f10q083112_ex31z1.htm EXHIBIT 31.1 SECTION 302 CERTIFICATION Exhibit 31.1 Section 302 Certification

Exhibit 31.1

 

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

 

I, Robert Lawrence, certify that:

 

 

1.

I have reviewed this Amended Quarterly Report on Form 10-Q/A of Pharma Investing News, Inc.;


2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 




Date: October 19, 2012

/s/ Robert Lawrence             

By: Robert Lawrence

Its: Chief Executive Officer

 

 

 




EX-31.2 3 f10q083112_ex31z2.htm EXHIBIT 31.2 SECTION 302 CERTIFICATION Exhibit 31.2 Section 302 Certification

Exhibit 31.02

 

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14

 

I, Robert Lawrence, certify that:

 

 

1.

I have reviewed this Amended Quarterly Report on Form 10-Q/A of Pharma Investing News, Inc.;


2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 




Date: October 19, 2012

/s/ Robert Lawrence            

By: Robert Lawrence

Its:  Chief Financial Officer

 

 

 

 




EX-32.1 4 f10q083112_ex32z1.htm EXHIBIT 32.1 SECTION 906 CERTIFICATION Exhibit 32.1 Section 906 Certification

Exhibit 32.01




CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Amended Quarterly Report of Pharma Investing News, Inc., (the “Company”) on Form 10-Q/A for the period ending August 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Lawrence, Chief Executive Officer and Chief Financial Officer, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

 




/s/ Robert Lawrence            

By: Robert Lawrence

Chief Executive Officer and Chief Financial Officer

 

Dated: October 19, 2012

 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.




EX-101.INS 5 phar-20120831.xml XBRL INSTANCE DOCUMENT 10-Q 2012-08-31 false PHARMA INVESTING NEWS, INC. 0001520047 --02-29 5361015 Smaller Reporting Company Yes No No 2013 Q2 4 12386 4 12386 6968 55472 47505 34891 54473 90363 0 0 5361 5182 19910 7538 -79740 -90697 -54469 -77977 4 12386 0.001 0.001 10000000 10000000 0 0 0 0 0.001 0.001 290000000 290000000 5361015 5181698 5361015 5181698 0 0 0 0 0 5000 5000 5000 1487 1321 2503 8383 10792 17792 31584 105857 -12279 -24113 -39087 -119240 39500 0 0 39500 27221 -24113 -39087 -79740 0.00 0.00 -0.01 5361015 5000000 5000000 0 0 1959 26584 -28543 39500 10957 0.00 5296973 10957 -39087 -79740 -39500 0 -39500 -9004 12382 46468 30000 0 34817 -7547 -26705 -37955 12551 0 25271 700 21826 30774 -18086 0 -18086 -4835 21826 37959 -12382 -4879 4 12386 9000 0 4 4121 0 0 0 0 0 0 <!--egx--><p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nature of Operations and Continuance of Business</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">Pharma Investing News, Inc. (the &#147;Company&#148;) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) 915, <i>Development Stage Entities.</i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><i><u>Going Concern</u></i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><i><u><font style="TEXT-DECORATION:none">&nbsp;</font></u></i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of August 31, 2012, the Company has not recognized any revenue, and has a working capital deficit of $54,469 and an accumulated deficit of $79,740. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company&#146;s future operations. These factors raise substantial doubt regarding the Company&#146;s ability to continue as a going concern.&nbsp; These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&nbsp; </p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.25in"><b>2.&nbsp;&nbsp;&nbsp;&nbsp; Summary of Significant Accounting Policies</b></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.25in"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">a)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Basis of Presentation</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;US GAAP&#148;) and are expressed in U.S. dollars. The Company&#146;s fiscal year end is February 28.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><font lang="EN-CA">b)&nbsp;&nbsp;&nbsp; Interim Financial Statements&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><font lang="EN-CA">&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company&#146;s audited financial statements and notes thereto for the period ended February 29, 2012.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company&#146;s financial position at August 31, 2012, and the results of its operations and cash flows for the three month periods ended August 31, 2012 and 2011. The results of operations for the period ended August 31, 2012 are not necessarily indicative of the results to be expected for future quarters or the full year.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">c)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Use of Estimates</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#146;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in; TEXT-AUTOSPACE:">d)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Cash and cash equivalents</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-AUTOSPACE:">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.&nbsp; </p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">e)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Basic and Diluted Net Loss per Share </p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company computes net loss per share in accordance with ASC 260, <i>Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (&#147;EPS&#148;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">f)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Financial Instruments</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Pursuant to ASC 820, <i>Fair Value Measurements and Disclosures </i>and ASC 825, <i>Financial Instruments</i>, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#146;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 1</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>&nbsp;</i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 2</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>&nbsp;</i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 3</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>&nbsp;</i></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company&#146;s financial instruments consist principally of cash, accounts payable and accrued liabilities, and amounts due to related parties.&nbsp; Pursuant to ASC 820, the fair value of our cash is determined based on &#147;Level 1&#148; inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. </p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp; Recent Accounting Pronouncements</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> <!--egx--><p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Related Party Transactions</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">During the six months ended August 31, 2012, the Company received $700 in additional cash loans from related parties, and had $30,000 in expenses paid on its behalf by a related party. The Company made cash payments on these notes totaling $18,086 during the six months ended August 31, 2012. Total related party notes payable as of August 31, 2012 were $47,505. The amount owing is unsecured, non-interest bearing, and due on demand.</p> <!--egx--><p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Common Shares</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">During the six months ended August 31, 2012, the Company issued 179,317 shares of common stock at an average of $0.07 per share for proceeds of $12,551.</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.25in"><b>5.&nbsp;&nbsp;&nbsp;&nbsp; Gain on Forgiveness of Debt</b></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.25in"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">On August 31, 2012, the Company settled outstanding professional fees of $69,500 for $30,000 of debt that was personally assumed by the President and CEO of the Company. </p> <!--egx--><p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>6.&nbsp; Subsequent Events&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">We have evaluated subsequent events through the date of issuance of the financial statements, and did not have any material recognizable subsequent events.</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">a)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Basis of Presentation</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#147;US GAAP&#148;) and are expressed in U.S. dollars. The Company&#146;s fiscal year end is February 28.</p> <!--egx--><p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><font lang="EN-CA">b)&nbsp;&nbsp;&nbsp; Interim Financial Statements&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in"><font lang="EN-CA">&nbsp;</font></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company&#146;s audited financial statements and notes thereto for the period ended February 29, 2012.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company&#146;s financial position at August 31, 2012, and the results of its operations and cash flows for the three month periods ended August 31, 2012 and 2011. The results of operations for the period ended August 31, 2012 are not necessarily indicative of the results to be expected for future quarters or the full year.</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">c)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Use of Estimates</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company&#146;s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in; TEXT-AUTOSPACE:">d)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Cash and cash equivalents</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in; TEXT-AUTOSPACE:">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.&nbsp; </p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">e)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Basic and Diluted Net Loss per Share </p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company computes net loss per share in accordance with ASC 260, <i>Earnings per Share</i>. ASC 260 requires presentation of both basic and diluted earnings per share (&#147;EPS&#148;) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">f)<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Financial Instruments</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Pursuant to ASC 820, <i>Fair Value Measurements and Disclosures </i>and ASC 825, <i>Financial Instruments</i>, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument&#146;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 1</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 2</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in"><i>Level 3</i></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.25in; MARGIN:0in 0in 0pt 0.25in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company&#146;s financial instruments consist principally of cash, accounts payable and accrued liabilities, and amounts due to related parties.&nbsp; Pursuant to ASC 820, the fair value of our cash is determined based on &#147;Level 1&#148; inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. </p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt">&nbsp;</p> <!--egx--><p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">g)&nbsp;&nbsp;&nbsp;&nbsp; Recent Accounting Pronouncements</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-0.25in; MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt 0.5in">The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.</p> 79740 54469 700 18086 30000 47505 179317 12551 0.07 69500 30000 0001520047 2012-03-01 2012-08-31 0001520047 2012-10-15 0001520047 2012-08-31 0001520047 2012-02-29 0001520047 2012-06-01 2012-08-31 0001520047 2011-06-01 2011-08-31 0001520047 2011-03-01 2011-08-31 0001520047 2011-02-08 2012-08-31 0001520047 2011-08-31 shares iso4217:USD iso4217:USD shares EX-101.CAL 6 phar-20120831_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 phar-20120831_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 phar-20120831_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Related party notes Details Net income (loss) for the period Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,361,015 and 5,181,698 common shares, respectively Current Liabilities Price per share of common stock issued The dollar amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. Recent Accounting Pronouncements Basis of Presentation Subsequent Events Cash Beginning of Period Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation). Gain on forgiveness of debt Preferred Stock, par or stated value Entity Voluntary Filers Going Concern Details Financial Instruments Interest paid LIABILITIES Cash Entity Registrant Name Document and Entity Information Proceeds from related party advances The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates. Accounts payable and accrued liabilities {1} Accounts payable and accrued liabilities Preferred Stock, shares outstanding Document Period End Date Common Stock Details Related Party Transactions {1} Related Party Transactions Nature of Operations and Continuance of Business {1} Nature of Operations and Continuance of Business Income tax paid Net Income (Loss) Common Stock, shares issued Current Fiscal Year End Date Amendment Flag Forgiveness of Debt Details Net loss before other income Consulting fees The charge during the reporting period towards consultation charges Accumulated deficit during the development stage Entity Current Reporting Status Proceeds from issuance of shares Gain on forgiveness of liabilities Amount represents the difference between the fair value of the payments made and the carrying amount of the debt at the time of its extinguishment. Operating Expenses {1} Operating Expenses Common Stock, par or stated value Entity Central Index Key Accumulated deficit The cumulative amount of the reporting entity's undistributed earnings or deficit. Gain on Forgiveness of Debt {1} Gain on Forgiveness of Debt Expenses paid by related party Changes in operating assets and liabilities: Additional paid-in capital Related party notes payable Repayments of related party advances The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates. Summary of Significant Accounting Policies {1} Summary of Significant Accounting Policies Proceeds from related party Common Stock, shares outstanding ASSETS Document Fiscal Year Focus Shares of common stock issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Supplemental Disclosures Weighted Average Shares Outstanding Basic and Diluted The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. STOCKHOLDERS DEFICIT Outstanding professional fees settled Outstanding professional fees settled Gain on Forgiveness of Debt Adjustments to reconcile net loss to cash used in operating activities Total Assets Entity Filer Category Working capital deficiency Excess of liabilities on assets used in operating activities as on date. Cash and cash equivalents Nature of Operations and Continuance of Business Net Cash Provided by (Used in) Financing Activities Professional fees Preferred Stock, shares authorized Total Liabilities and Stockholders Deficit Total Stockholders Deficit Due to related parties Expenses paid by a related party Expenses paid by a related party Common Stock Repayments to related party Net Cash Used In Operating Activities Net Loss per Share Basic and Diluted Accounts payable and accrued liabilities Statement [Line Items] Document Fiscal Period Focus Entity Common Stock, Shares Outstanding Value of common stock issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. Basic and Diluted Net Loss per Share Interim Financial Statements Subsequent Events {1} Subsequent Events Summary of Significant Accounting Policies Increase (Decrease) in Cash Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares Entity Well-known Seasoned Issuer Debt settled Debt settled Use of Estimates Related Party Transactions Cash End of Period Cash End of Period Revenues Stockholders equity number of shares par value and other disclosures Statement [Table] Accounting Policies (POLICIES) Common Stock {1} Common Stock Financing Activities Other Income {1} Other Income General and administrative Total Liabilities Document Type Related Party advances Details Operating Activities Common Stock, shares authorized Preferred Stock, shares issued EX-101.PRE 9 phar-20120831_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 phar-20120831.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000170 - Statement - Forgiveness of Debt (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000150 - Statement - Related party notes (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Nature of Operations and Continuance of Business link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Condensed Balance Sheets Parentheticals link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Condensed Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Accounting Policies (POLICIES) link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Common Stock link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000160 - Statement - Common Stock (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000130 - Statement - Going Concern (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Gain on Forgiveness of Debt link:presentationLink link:definitionLink link:calculationLink 000140 - Statement - Related Party advances (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Condensed Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink GRAPHIC 11 f10q083112_10qz002.gif IMAGE begin 644 f10q083112_10qz002.gif M1TE&.#EAPP"&`/<`````````,P``9@``F0``S```_P`S```S,P`S9@`SF0`S MS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9_P#,``#, M,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`9C,`F3,` MS#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F_S.9`#.9 M,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_9C/_F3/_ MS#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S_V9F`&9F M,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,9F;,F6;, MS&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`_YDS`)DS M,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF99IF9F9F9 MS)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G__\P``,P` M,\P`9LP`FN7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7?^[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUS_ M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR#SC777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS34`N7;MVK5KUZY=NW;MVK5KUZY=N_;ERZ`O7[P,^O+E M2Z(O7P9]^>+E2Z)$K69=NX;NVK5KUZY=:_7ERYN7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU+SMV?-GQ9<>.+SIV9-FA MX\N.+SN^Z,BRXTNK:]>N7;MV[5JB+SMV?$ET[=JU:]>N77/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS37_UUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--=?L M\$4-7^Q0PQ<[?+'#%SM\L<,.7^RP0PU?[+##%SI\,N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=J7'5]V9$ET[=JU:]>N M7;MV[=JU:ZT2?=GQ9<>.+SH&7;MV32)?[)#%#HE<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS_\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/-#CM\L8,.B5QSS3777'/--==<<\TUUUQSS36([/"%#CM\L<,UUUR3R`Y? M[/!%(M=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<__--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777*/#%S7L\$4BUUQSS3777'/--==<<\TU MUUQSS36#[%##%SOLT,HUUR3RQ0X[T)#(-==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUP#D&O7KEV[=NW:M6O7 MKEV[=NW:M6O_UZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZ[M^++CRXY$ MUZY=NW;MVK5KUZY=NW;MVK5KUW9\V?%EQY=KUQ+M\++C2Z)KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW8MRXX=7FHD_[IV[=JU M:]>N7;MV[=HUUUQSS377)++#%S5XL<,UUR22Q0Y?[)#(-==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 MH'/--=?L\,4..WR1R#777'/--==<<\TUU_]<<\TUUUQSS36)>+'##CM\<)M#++-==<<\TUUUQSS3777'/--==<,TLK MB23RQ2!E#)((*[-<<\TUUUQSS3777'/--==<<\TUUUQSS36SM)+(%U]<<\TU MUUQSS3777'--*ZTD\L47B21RS3777'/--==<<\TUK212QB!?)))(--=<<\TU MUUQSS3777'/--==<<\TLK20RR!=?)/)%(JW,RP0Q8[[/#%#E^T/'%#CMXL<,.6>Q01BO77'/- M-=-+ MHFO7KEV[=NW:M6O7KEV[=NW:M6NMONS8\67'M6N)LNSXLJ/5M40U=GS9_['C MRXX=7W34^+*CU;5KUZY=NW;MVJPO7W;LR+)CQY<=7W9\J?%EQXXOUZY=NW;M MVHXO.W9\N7:ME8XO.W9DV;$CT9<=7W9[+###E_HL,,7 MUUQSS377Z)#%#E]X<4TK.V2Q@PY?[+##%XGHD,4..USSQ0XU[/#%#E_LL,,7 M.WRQPPY?S#++%UGLL,,..WRQPQ<[[/!%#5_HD,@UUUQSS377M/+%#CMDL<,. M7^SPQ0X[?+'#%SM\L<,.7UQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQS#3K77'/-#CMDL<,.B5QSS3777'/--==<<\TUUUQSS3777#.(#CM\L<,7 MUUR3B!<[?%'#%SOLL,,7.WCQ12)?>+'##E_L4,,77UQSS3777'.-%SOLL,,7 M.GSQQ1>))/+%%U_L\$7_#5_L\$4KUUQSS34[[/#%#E]<\\4.7^SPQ0X[?+'# M*3OL\,4.@^SPQ0Y?Z/!%(E]XL<,.-7RAPPZ#>+'##E_L\,47B'SQQ1T\L47.WRQ M0Q8[?+&#%P!I=>W:M6O79GW9H>-+C2^)KEV[=BW1%QTUONP8-.O:M6O7KEV[ M]F7'EQU?=GBY=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6L[L.SX MLB/1M6O7KEV[=NW:M6O7KEV[=NW:EQU?:GC9T>K:M40[=NSXLF/'EU;7KEV[ M=NW:M6NMONCXLF-'HFO7KEW[LF.'EQV#KEV[=NW:M6O7KEU+M&/'%QT[KEV[ M=NU+#2\[ONSXHF-'HFC7KEV[EFC'EQTUONSX[/#%#CM\<SPQ0Y?S'+--==<<\TU MUUQSS2!>[/#%#E]\<N7;MV[=JU:]>N7?NB8\>7'=>N74NTP\N.'?^MKEV[=NW:M6O7 MKEV[=NW+EQU8=ER[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEU#=^W:M1T[ M=GS9L2/+CB\[ONSXHN/+CB\[=GRIL6/'EQI?KEV[=NU:HAU?:NCX+'#%SNTN7;MV[=JU M:ZUV?-GAIN7;MV[=JU:]>N?=&QX\N.:]>N7;MV[=JU6:T&?=F19<>7 M&CN^U/BR8\>7'3NN7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>NH;MV[=J. M+SN^[$AT[=JU:]>N7;MV[=JU:]>N7;O_=NW:M6O7KEV[=BW1ER\[LB2Z=NW: MM6O7KEV[=NW:M6M?O.RH\>7:M6O7KEUK-6C'EQU>=NSXLF/'EQT[ONS8L>/+ MCFO7KEW;\65'C2_7KEV[=NW:M6O7KB6J\67'CE;7KEV[=NW:M6O7KEUKI6/' MCB]?KEV[=NW:M6O7KEV[=FU'EAT[OER[=NW:M6NMRGS1\67'CB\Z=GS9L>.+ M#E_LL,,7.EQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777/.% M#COL\$4BUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUR1"PPX[?('( M-==<<\TUUUQS_\TUUUQSS35?[+##%SM<<\TUUUSSA1<[?+'##E_L\(4..WRA MPQ>)S#+(#E_0\,4UUUQSS1+'##E\DTDHKLUQSS377>+'#%SOL<,TUUURS0Q8[?$'#-==< M<\TUUUQSS377)/+%#CM\T)7'/--==< M<\TUUUQSS3777//%%S1\L<,UUUR3R!N7;MV[5JB'32^[)AU[=JU:]>N7;MV M[=JU63NR[-#QY=JU:]>N7;MV[=JU:]=J?-FQ8\>U:]<&[?BRP\N.+ZVN7;MV M[=JU:]>N7?OR98>7'=>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]?07;MV M;<>7'3N^#+IV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;N6*(N.+SL27;MV M[=JU:]>N7;MV[=JU,CMV[/AR[=JU'3J^[-@QZ-JU:]>N7;MV[=JU:]>^[/BR MH\:U:]>N[=CQ9<>7_VO7KEV[=NW:M6O7$GW9L>-+JVO7KEV[=NW:M6O7KK7Z MLN/+CD'7KEV[=NW:M6O7KEV[MD-'EAU?KEUKM>.+CAT[#'+--==<<\TUUUQS MS3777//%%SO4\,4UUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS35?Z)#%#E\D#7'/--==<<\TUUUQSS3777//%%SM\4<,UU[2RPQ<[?*'#-==<<\TUUUQS MS3777'/--5]\L8,7.UQSS377U/#%#ECL<,TUUUQSS3777'/--8G4\,4.7_^T MTHL,.7^Q0QC777'/--==<<\TUUUQSS0Y?[/#%#M=< MT\H.7]3PQ1?77'/--==<<\TUUUQSS377?*'##E_L<,TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<+'#%SMX M<R0Q0X[#'+--==<<\TUUUQSS3777'/-#C5\L<,7UUQSS35>[+##%SM< M<\TUUUQSS3777'--(CM\H<,.K5QSS3777'/--=?_7'/--;-\L4,-7WQQS377 M7'/--==<<\TUUURS0PU?Z+##-=)7'/--==<<\TUUUQSS34`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`Y!KUZY=NW;MW+5KUZY=NW9M5J)$7[Y\^9(H M4;1KUZY=NW:MU9N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=HUUUQSS377 M7'/--==<<\TUUUQSS3777(/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR#SC77 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-->A<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TU_]=<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--=>@<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSSC777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/-->A<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--?_77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777(/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUZ%QSS3777'/- M-==<A<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.M=<=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@<\TUU\B`0``'!&#% M-=?_7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS14''"#``8%<<\TUUUQSS36LL,(**XA$<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUZ%QS MS3777'/--==<<\TU,@2`P`$"R'#--=<`Y-JU:]>N7;MV_^W:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NU:(`0!#@3H@<\TUUUQSS3777'/-_S77L-+%%5;( M<$4@K%QSS3777'/--==<<\TUUUQSS377L!*(%3)$(4,@>[!RS3777'/--==< M<\TUUP0BP`$F'!#(-==<@\XUUUQSS3777'/--==<<\TUUUQSS3777'/--=>P M$L@55LAP11>F7(/.-==<<\TUUUQSS3777'/--==N78-R`$$`!"RN7;MV+1""`P$.L+IVC965``<"K`B` M(,"!`S)87;MV[=J5`P<$'&!Q[=JU:]>N7;MV[=JU:]>NF3H0X$``%M>N7;MV M[=JU+BP.!#B`(,"!``A6!)IU[=JU:__7KEV[=NT:*RL'!!Q`$.!`@`,'`K"P M$NW:M6NL#@@X(.!`@`,'`AQ`$`!!@`/7K@4Z(."``%;7KET+=.!`@`/7KET3 MQ.)`@`,(`AQ8$>"`E5;7KEV[=NW:M6O7KEV;%6B%@`,(`JP(<.``"T'7K@42 M<$!`@&O7KJ&[=NV:#`$'`ARPP M@$``!Y0@PS777'--(`<<(,`*5@2`P`$!',""#%?(L,(!!P1P0``KS'#--==T M$<`!`:S``CK77'/--==<<\TUUUQS#2L('"#``2Q<<\TUUUP1``(!!'!```?( M<(4,+!QP@``'"'#``:9<<\TUUUQQ0``'!(#``0>P8,45,K!P@``''!#``0>P MPDH``1P0P`$'"'#``0$<$,`!!P1PS35=(/\0P`$'L'+--==T<8``!QRPQP$" M'!```BS(<(4,!P1PP`$"K!#`%==<@\XUUUPCR`$!('!```<NR3@0X``"%M>N7;NV!T&``P$0!#@0(!"K:]>N M7;LF"$&``P@"'&!U[5JK`P@"(#C`ZMJU:]>N7;MV[=HU=%<.!#@00-"U:]<$ M'3@0X,`!&8*N7;MV[1JK*P<"'#@@X,"L:]=F!3AP0,"!%8*N7;MV[=HU5C(. M!$!P0("56:Q8L6)U)<`*!`&NL&+%2A"K:]<"!3@@X`"K:]>N[3D0`$&``P$. M(`C$ZMJU:]>N!4+_$.!```0!KEV[=NU:JQ4(`AP(<.`*JVO7KEV[QDI&@`,' M!!P0<"#`M6O7T%V[=HT%BP,"#LBX=NW:M2X'`B`(<.```E;7KEV[=NW:M6NL M$!P(<$!`EVO7KK$X<"#``4'77'/--==<<\TUUUQS#0L'(!#``==<P MA<<\TUUUQS32`! M'!#``8%<<\TUUW1Q0``'!!#(-==<<\TUUUS310`('!``*]=<L!#@0X`"+:]>N70L4`,$!`0=87;MV[=JU M:]>N7;MV[1J+`P$0!+AV[=HU*P<"'!`0Z-JU:]>N7;MV[1H+`0<.'+AV[9J@ M%0(.'+AR[=JU:]>N7;MV[=JU:]>N!4!P(`"+:U<0!$`0@,6U:]>NH;MV[=JU M:]=8L4+$BA6K:]>N70L4`$$`!%VN7;MV[=JU:X$.!#@0`-&U:]?V(`B`X`"" M:]>N7;MV[=JU:]>N7;MVX$"``S*N7;NVXH"``P<$7;MV[=JU:]>N7;MV[=JU M*P<$'!!P`-VU:^BN7;O&`L$!`0>L7+MV[5H7!`$.'&!Q[=JU:]>N7;MV[=JU M_VO76""P0@`'7'/--=<@$L`!"!S`PC777'/--==<T$L@!!P1PP`$LL((..M=< M<\TUUUQSS3777'/--==<<\TUUW0AP`$K!!#(-==<<\TUUUQSA0`'!(``*]=< M=<<\TUUUQSS3777!,``@<(8,4UU[`2``('!,#"-==< M<\TUUUQSS3777'/--=>PP$,`!`1S`RC77 M7'/--==@$@,`!`AQPS377 MH'/--=?((,`!!P0@PS777'--%P@$<$``@5QSS3777'/--==<<\TUUUS#P@$! M''#`-==<<\TU5QP@P`$!=''_S3777'/--=>P<$``![!PS377M'+``0&L@``4 M,ES!@A4R6"&#%2Q8P8(5,D#!0@`'"'!`(-<$$L`!!P2`P`$!''``"U8$PLHU MUUQSS3777'/--==<Z'!!P(,`!`0<$'#@@ MX(``*X%:7;MV[=JU:]>N[3EP(,"!+M>N7;MV[=JU0"40!#C`ZMJU:UT0!$`0 M@-6U:]>N7;MV[=JU:]>N70MPX(``&=?0L3APH,2!+M>N7;MV[=JU:]>N7;MV M[=HU&0$.(`AP[=HU=->N76.!X$"``S*N7;MVKP M$@`"`1R`0``(!(#``0$<<(``!P1P0``('!#``0$@<``+Z/]<!7!%(%X%<$4@7@5P12!=[=!%(%WL(N7;MV[=JU:]>N'0APX`"+:]>N'`APX,"5:]>N7;MV[=JU:]>N M7;MV#5T`!`$0'$!W[1JZ:]>NL3APX$``5EQSS3777('``0$<$,@UUUQSS377 M7'/--==<<\TU+"!P@``'7'/--==<<\TU@1P0``(!=''--=>P<$``!UQQS377 M7'/--0BL(,`!!UQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUPCR`$(!'!```<(QR`0`D'=''--==<<\TUUP1R``(!',#*-==<$\@!"`1P@"#77'/--==<<\TU MUUQSS377'!#`_P$'L'#--8@$<$``!QQPS3777'/--==<<\TUUUQSS357'"#` M"@(<<,TUUZ!SS377R(!```<$(,,UUUQS31<"'!#``8%<<\TUUUQSS3777'/- M-==UUQSS3777'/--==<<\TUUUQCQ0$('!!`(`@<<$``5UQSS3777'/- M-==<<\TUUUQSQ0$!'%""#-=<QR`0``'L'+--==T<4``!R#`RC777'/--==<<\TUUUQSS34!('!`"3)<<\TU M@AR`0``'''`%.M=<<\TUUUQSS377L(+``0$<(,`!`:!SS3777'/--58$<$`` M"+!PS3777!/(`0$<_Q!`%]=<<\TUUUQSS3777'/--==8$<`!"`1PS3777'/- M-==<7`@0,'#APP<0#!M6O7KEV[=LU*@`,!#K"X=NW:M4`!#AP($.C: MM6O7KEV[=NW:M6O7KEDY$.!`@&O7KEV[=NW:M6O_UV0(."#@P($`!UA=NW;M MVK5KUZY=NW:-Q8$`!P0<$+!B1I=`5ZP$.'`@P`$!!ZY=NW;MRH$#`0X$.!#` MRI5`@;I8$7`@P($`!PX$NG;MVC56`@X(.(`@P($#`@YW:M6O7KEV[=HV5C`,!#@0X$.#`M6M7#@0X M$(#5M6O7N@0X$.``JVO7KEV[=NW:M6O7KEV[%N!`@`,LKEV[=NW:M6O7K@5B M<2#`@0`!#@1@T>7:M6M7`B`(<.#:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O76`6Z(H.%#!96NK"Z=NW:M6O7KEV[=NW:M6O76`7: M(X.%#!8RK@1B=>W:M6O7KEV[_W;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;--==<<\TUUUQSS377S,)* M(%T$@@@KUUQSS3776'%```@<<,TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<__--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS34'!'!``#*@<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/_S3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQCR@$"'("`%==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777`.0:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV_^W:M6O7KEV[=NW:M6O7KEV3(>!```2L MKEV[=NW:M6O7KEV[=NV:C`,!#@00=.W:M6O7KEU+].7+ET%?KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW+ET%?OER[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:-==<<\TUUUQSS3777'/--==<N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N76-UX("` M`P$.(&!Q)5"@0"P.(`AP0,`!`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`Y!KUW;L^++#RY=$ MUZY=NW;M6J(O.[[LV($ET;5KK;SL^++#R[5KUZY=NW;MVK5$.W3L^%+CRXYK MUZY=NW;MVK5KB7;L^+*CU;5$7W;4^+*C3+1KUZY=NW8MT9<=.[[4V-'JVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW8-'3ITZ-"ANW;MVK4O_SJ^[/`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``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`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``$'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT &Z`("`@`[ ` end XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Common Stock
6 Months Ended
Aug. 31, 2012
Common Stock  
Common Stock

4.             Common Shares

 

During the six months ended August 31, 2012, the Company issued 179,317 shares of common stock at an average of $0.07 per share for proceeds of $12,551.

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P,F,X9CEB,U\U,3@R7S1C9#-?834T8E\U-V8S M9C!D,#DS.3`B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O5]4#I7;W)K#I7;W)K M#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D%C8V]U;G1I;F=?4&]L:6-I97-?4$],24-)15,\+W@Z3F%M93X-"B`@ M("`\>#I7;W)K#I7;W)K#I7 M;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H M:7,@<&%G92!S:&]U;&0@8F4@;W!E;F5D('=I=&@@36EC'1087)T7S`R8SAF.6(S7S4Q.#)?-&-D,U]A-31B7S4W9C-F,&0P M.3,Y,`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P,F,X9CEB,U\U M,3@R7S1C9#-?834T8E\U-V8S9C!D,#DS.3`O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!296=I'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!6;VQU;G1A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P,F,X9CEB M,U\U,3@R7S1C9#-?834T8E\U-V8S9C!D,#DS.3`-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,#)C.&8Y8C-?-3$X,E\T8V0S7V$U-&)?-3=F,V8P M9#`Y,SDP+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D.B`R.3`L,#`P+#`P,"!C;VUM;VX@3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P,F,X9CEB,U\U,3@R7S1C9#-?834T8E\U M-V8S9C!D,#DS.3`-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#)C M.&8Y8C-?-3$X,E\T8V0S7V$U-&)?-3=F,V8P9#`Y,SDP+U=O'0O:'1M;#L@8VAAF5D/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XR.3`L,#`P+#`P,#QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA6%B M;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@ M8VQA2!R96QA=&5D('!A'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H57-E9"!I;BD@1FEN86YC M:6YG($%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X- M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T M)SX\8CXF;F)S<#L\+V(^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..FIU M2`X+"`R,#$Q+B!4:&4@0V]M<&%N>2!I6QE/3-$)U1%6%0M04Q) M1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N,C5I;B<^/&D^/'4^ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF M>3L@34%21TE..C!I;B`P:6X@,'!T(#`N,C5I;B<^5&AE2!A28C,30V M.W,@9G5T=7)E(&]P97)A=&EO;G,N(%1H97-E(&9A8W1O2!A;F0@8VQA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/"$M+65G>"TM/CQP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z+3`N M,C5I;CL@34%21TE..C!I;B`P:6X@,'!T(#`N,C5I;B<^/&(^,BXF;F)S<#LF M;F)S<#LF;F)S<#LF;F)S<#L@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S/"]B/CPO<#X@/'`@6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P M:6X@,'!T(#`N,C5I;B<^)FYB2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E'!R97-S960@:6X@52Y3 M+B!D;VQL87)S+B!4:&4@0V]M<&%N>28C,30V.W,@9FES8V%L('EE87(@96YD M(&ES($9E8G)U87)Y(#(X+CPO<#X@/'`@2!D;R!N;W0@:6YC;'5D92!A;&P@;V8@=&AE(&EN9F]R;6%T:6]N(&%N M9"!F;V]T;F]T97,@28C,30V.W,@875D:71E9"!F:6YA;F-I86P@2`R M.2P@,C`Q,BX\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SXF;F)S<#L\+W`^(#QP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N M-6EN)SY4:&4@9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D960@:&5R96EN M(&%R92!U;F%U9&ET960[(&AO=V5V97(L('1H97D@8V]N=&%I;B!A;&P@;F]R M;6%L(')E8W5R2!T M;R!P2!T:&4@0V]M<&%N>28C,30V.W,@9FEN86YC:6%L M('!O'!E8W1E9"!F;W(@9G5T M=7)E('%U87)T97)S(&]R('1H92!F=6QL('EE87(N/"]P/B`\<"!S='EL93TS M1"=415A4+4%,24=..FIU'!E;G-E2!E=F%L=6%T97,@97-T:6UA M=&5S(&%N9"!A2!B87-E6EN9R!V86QU97,@;V8@87-S971S(&%N9"!L:6%B:6QI M=&EE2!D:69F97(@;6%T97)I86QL>2!A;F0@861V97)S96QY(&9R;VT@ M=&AE($-O;7!A;GDF(S$T-CMS(&5S=&EM871E6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N M-6EN)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF M>3L@5$585"U)3D1%3E0Z+3`N,C5I;CL@34%21TE..C!I;B`P:6X@,'!T(#`N M-6EN.R!415A4+4%55$]34$%#13HG/F0I/&9O;G0@2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT M960@879E2!IF%T M:6]N('=I=&AI;B!T:&4@9F%I2!B92!U6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T M(#`N-6EN)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S M=&EF>3L@5$585"U)3D1%3E0Z,"XR-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0@ M,"XR-6EN)SX\:3Y,979E;"`Q/"]I/CPO<#X@/'`@6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P M:6X@,'!T(#`N-6EN)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q) M1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z,"XR-6EN.R!-05)'24XZ,&EN(#!I M;B`P<'0@,"XR-6EN)SX\:3Y,979E;"`R/"]I/CPO<#X@/'`@2P@;V)S97)V86)L M92!M87)K970@9&%T82X\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S M=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SXF;F)S<#L\+W`^(#QP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z,"XR M-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0@,"XR-6EN)SX\:3Y,979E;"`S/"]I M/CPO<#X@/'`@6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SY,979E;"`S(&%P<&QI97,@=&\@ M87-S971S(&]R(&QI86)I;&ET:65S(&9O&EM M871E('1H96ER(&-U6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z+3`N,C5I;CL@34%21TE. M.C!I;B`P:6X@,'!T(#`N-6EN)SYG*29N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R!296-E;G0@06-C;W5N=&EN9R!02!O=&AE'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+65G M>"TM/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I M;B`P:6X@,'!T)SX\8CXS+B9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P M.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R9N8G-P.R!2 M96QA=&5D(%!A6QE/3-$ M)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T)SX\8CXF M;F)S<#L\+V(^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..FIU6UE;G1S(&]N('1H97-E(&YO=&5S('1O=&%L:6YG("0Q M."PP.#8@9'5R:6YG('1H92!S:7@@;6]N=&AS(&5N9&5D($%U9W5S="`S,2P@ M,C`Q,BX@5&]T86P@2!N;W1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A"!M;VYT:',@96YD960@075G=7-T(#,Q+"`R,#$R+"!T:&4@ M0V]M<&%N>2!I'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z+3`N,C5I;CL@34%21TE. M.C!I;B`P:6X@,'!T(#`N,C5I;B<^/&(^-2XF;F)S<#LF;F)S<#LF;F)S<#LF M;F)S<#L@1V%I;B!O;B!&;W)G:79E;F5S2X@/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T M)SX\8CXF;F)S<#L\+V(^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..FIU MF%B;&4@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@ M,'!T(#`N,C5I;B<^)FYB2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E'!R97-S960@:6X@52Y3+B!D M;VQL87)S+B!4:&4@0V]M<&%N>28C,30V.W,@9FES8V%L('EE87(@96YD(&ES M($9E8G)U87)Y(#(X+CPO<#X\6QE/3-$)U1%6%0M04Q) M1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N,C5I;B<^/&9O;G0@ M;&%N9STS1$5.+4-!/B9N8G-P.SPO9F]N=#X\+W`^(#QP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SY4 M:&5S92!I;G1E2!G96YE2!C;VYT86EN(&%L;"!N;W)M M86P@2!I;F1I M8V%T:79E(&]F('1H92!R97-U;'1S('1O(&)E(&5X<&5C=&5D(&9O65A6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N M-6EN)SY4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E;65N=',@ M:6X@8V]N9F]R;6ET>2!W:71H(%53($=!05`@2!R96=U;&%R;'D@979A;'5A=&5S(&5S=&EM871E"!A M'!E'!E;G-E2!A<'!A'!E2!T:&4@0V]M<&%N>2!M87D@9&EF M9F5R(&UA=&5R:6%L;'D@86YD(&%D=F5R2!F'1E;G0@=&AE'0^/"$M+65G M>"TM/CQP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1% M3E0Z+3`N,C5I;CL@34%21TE..C!I;B`P:6X@,'!T(#`N-6EN.R!415A4+4%5 M5$]34$%#13HG/F0I/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ:G5S M=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SY4:&4@0V]M<&%N>2!C M;VUP=71E2!S=&]C:R!M971H;V0@86YD(&-O;G9E6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%2 M1TE..C!I;B`P:6X@,'!T(#`N,C5I;B<^)FYB&EM:7IE('1H92!U2!I6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M5$585"U)3D1%3E0Z,"XR-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0@,"XR-6EN M)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T(#`N-6EN)SY,979E;"`R(&%P<&QI97,@=&\@ M87-S971S(&]R(&QI86)I;&ET:65S(&9O2P@;V)S97)V86)L92!M87)K970@9&%T82X\+W`^(#QP('-T>6QE M/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@34%21TE..C!I;B`P:6X@,'!T(#`N M-6EN)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF M>3L@5$585"U)3D1%3E0Z,"XR-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0@,"XR M-6EN)SX\:3Y,979E;"`S/"]I/CPO<#X@/'`@6%B M;&4@86YD(&%C8W)U960@;&EA8FEL:71I97,L(&%N9"!A;6]U;G1S(&1U92!T M;R!R96QA=&5D('!A2!D M871E7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A9'9A;F-E6UE;G1S(&]F(')E;&%T960@<&%R='D@861V86YC97,\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!A M(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\P,F,X9CEB,U\U,3@R7S1C9#-?834T8E\U-V8S9C!D,#DS.3`-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#)C.&8Y8C-?-3$X,E\T8V0S M7V$U-&)?-3=F,V8P9#`Y,SDP+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!N M;W1E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P,F,X9CEB,U\U,3@R7S1C9#-?834T8E\U-V8S9C!D,#DS.3`- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,#)C.&8Y8C-?-3$X,E\T M8V0S7V$U-&)?-3=F,V8P9#`Y,SDP+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R&UL/@T*+2TM+2TM/5].97AT M4&%R=%\P,F,X9CEB,U\U,3@R7S1C9#-?834T8E\U-V8S9C!D,#DS.3`M+0T* ` end XML 15 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party Transactions
6 Months Ended
Aug. 31, 2012
Related Party Transactions  
Related Party Transactions

3.             Related Party Transactions

 

During the six months ended August 31, 2012, the Company received $700 in additional cash loans from related parties, and had $30,000 in expenses paid on its behalf by a related party. The Company made cash payments on these notes totaling $18,086 during the six months ended August 31, 2012. Total related party notes payable as of August 31, 2012 were $47,505. The amount owing is unsecured, non-interest bearing, and due on demand.

XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Balance Sheets (USD $)
Aug. 31, 2012
Feb. 29, 2012
ASSETS    
Cash $ 4 $ 12,386
Total Assets 4 12,386
Current Liabilities    
Accounts payable and accrued liabilities 6,968 55,472
Due to related parties 47,505 34,891
Total Liabilities 54,473 90,363
STOCKHOLDERS DEFICIT    
Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares 0 0
Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,361,015 and 5,181,698 common shares, respectively 5,361 5,182
Additional paid-in capital 19,910 7,538
Accumulated deficit during the development stage (79,740) (90,697)
Total Stockholders Deficit (54,469) (77,977)
Total Liabilities and Stockholders Deficit $ 4 $ 12,386
XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Nature of Operations and Continuance of Business
6 Months Ended
Aug. 31, 2012
Nature of Operations and Continuance of Business  
Nature of Operations and Continuance of Business

1.             Nature of Operations and Continuance of Business

 

Pharma Investing News, Inc. (the “Company”) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.

 

Going Concern

 

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of August 31, 2012, the Company has not recognized any revenue, and has a working capital deficit of $54,469 and an accumulated deficit of $79,740. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.  These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. 

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Summary of Significant Accounting Policies
6 Months Ended
Aug. 31, 2012
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

2.     Summary of Significant Accounting Policies

 

a)       Basis of Presentation

 

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28.

 

b)    Interim Financial Statements           

 

These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the period ended February 29, 2012.

 

The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at August 31, 2012, and the results of its operations and cash flows for the three month periods ended August 31, 2012 and 2011. The results of operations for the period ended August 31, 2012 are not necessarily indicative of the results to be expected for future quarters or the full year.

 

c)       Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

d)       Cash and cash equivalents

 

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. 

 

e)       Basic and Diluted Net Loss per Share

 

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.

 

f)        Financial Instruments

 

Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, and amounts due to related parties.  Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

 

g)     Recent Accounting Pronouncements

 

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Balance Sheets Parentheticals (USD $)
Aug. 31, 2012
Feb. 29, 2012
Preferred Stock, par or stated value $ 0.001 $ 0.001
Preferred Stock, shares authorized 10,000,000 10,000,000
Preferred Stock, shares issued 0 0
Preferred Stock, shares outstanding 0 0
Common Stock, par or stated value $ 0.001 $ 0.001
Common Stock, shares authorized 290,000,000 290,000,000
Common Stock, shares issued 5,361,015 5,181,698
Common Stock, shares outstanding 5,361,015 5,181,698
XML 21 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Forgiveness of Debt (DETAILS) (USD $)
Aug. 31, 2012
Outstanding professional fees settled $ 69,500
Debt settled $ 30,000
XML 22 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information
6 Months Ended
Aug. 31, 2012
Oct. 15, 2012
Document and Entity Information    
Entity Registrant Name PHARMA INVESTING NEWS, INC.  
Document Type 10-Q  
Document Period End Date Aug. 31, 2012  
Amendment Flag false  
Entity Central Index Key 0001520047  
Current Fiscal Year End Date --02-29  
Entity Common Stock, Shares Outstanding   5,361,015
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Document Fiscal Year Focus 2013  
Document Fiscal Period Focus Q2  
XML 23 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Statements of Operations (USD $)
3 Months Ended 6 Months Ended 19 Months Ended
Aug. 31, 2012
Aug. 31, 2011
Aug. 31, 2012
Aug. 31, 2011
Aug. 31, 2012
Revenues $ 0 $ 0 $ 0 $ 0 $ 0
Operating Expenses          
Consulting fees 0 5,000 0 5,000 5,000
General and administrative 1,487 1,321 1,959 2,503 8,383
Professional fees 10,792 17,792 26,584 31,584 105,857
Net loss before other income (12,279) (24,113) (28,543) (39,087) (119,240)
Other Income          
Gain on forgiveness of debt 39,500 0 39,500 0 39,500
Net Income (Loss) $ 27,221 $ (24,113) $ 10,957 $ (39,087) $ (79,740)
Net Loss per Share Basic and Diluted $ 0.00 $ 0.00 $ 0.00 $ (0.01)  
Weighted Average Shares Outstanding Basic and Diluted 5,361,015 5,000,000 5,296,973 5,000,000  
XML 24 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting Policies (POLICIES)
6 Months Ended
Aug. 31, 2012
Accounting Policies (POLICIES)  
Basis of Presentation

a)       Basis of Presentation

 

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28.

Interim Financial Statements

b)    Interim Financial Statements           

 

These interim unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the period ended February 29, 2012.

 

The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position at August 31, 2012, and the results of its operations and cash flows for the three month periods ended August 31, 2012 and 2011. The results of operations for the period ended August 31, 2012 are not necessarily indicative of the results to be expected for future quarters or the full year.

Use of Estimates

c)       Use of Estimates

 

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Cash and cash equivalents

d)       Cash and cash equivalents

 

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents. 

Basic and Diluted Net Loss per Share

e)       Basic and Diluted Net Loss per Share

 

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.

Financial Instruments

f)       Financial Instruments

 

Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

 

Level 1

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The Company’s financial instruments consist principally of cash, accounts payable and accrued liabilities, and amounts due to related parties.  Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

 

Recent Accounting Pronouncements

g)     Recent Accounting Pronouncements

 

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 25 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Subsequent Events
6 Months Ended
Aug. 31, 2012
Subsequent Events  
Subsequent Events

6.  Subsequent Events       

 

We have evaluated subsequent events through the date of issuance of the financial statements, and did not have any material recognizable subsequent events.

XML 26 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related party notes (DETAILS) (USD $)
Aug. 31, 2012
Related party notes payable $ 47,505
XML 27 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Going Concern (DETAILS) (USD $)
Aug. 31, 2012
Accumulated deficit $ 79,740
Working capital deficiency $ 54,469
XML 28 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Related Party advances (DETAILS) (USD $)
6 Months Ended
Aug. 31, 2012
Proceeds from related party advances $ 700
Repayments of related party advances 18,086
Expenses paid by a related party $ 30,000
XML 29 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Common Stock (DETAILS) (USD $)
Aug. 31, 2012
Shares of common stock issued 179,317
Value of common stock issued $ 12,551
Price per share of common stock issued $ 0.07
ZIP 30 0001078782-12-002687-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001078782-12-002687-xbrl.zip M4$L#!!0````(`"`P5D&(_7GP_AH``+G*```1`!P`<&AAN">%ZWPZ,BO5(X,[?=<2SO#3D9!NN=UN=LKF MT=]__)___N%OY;)QY[E6T.>6T9L9EQ=?NO3F2>&(]_X'`,8,QR MU2S7S:-P^$#8\7`$/QDQ;\R$\\2E#]-T^%0B'GRS5FW'[Z7>(32N-X1!U?JQ M<*2/1D,71J;I MP<<])A/(\%1L0'\@RT/&)O$;`R9[-#I\D,%4$(U&S6SE(5$CHA><8)P]V/*] M8W\VX<#PQBW"E"_'0DQ7AB MXS3INY''!Y^.TPNW#U0X_B.\;O1=Q^?/_CV^=0'C MZU7S_T(1^=&LEG_YX7C^E04X=S`CU[ITK`OFYP-$BLJ@!G4S#38%(8;?A4<6 M/KZRV3`7[H#9DBN0J9=B4)>.+_S9/1\*Z7O,\6_8.)_2NW]T[W_N&MLZ\=BS__D\]R\55!C9JPZHV6#GX. M0@S_//`\G**0?6;_FS-O'>:7R]5:N=91\)=!F)^".QZ[SH/O]K\]@$AQ>1OX MJ%9H.HW`$0J3>G24PGYMUDR8TI%A\;X8P_K`5S=71S\VZR?X?6J6.4CFZ+D2 M-O?.@NI0R`'^O# M7P)A0?T3&;J";_)G``:@GE;]N;>70%<&8C7\7VI9T+6W"7YH\4_/F1PE4OSU MX6)!A)6KG!/AQ@_'.H1-0=9JG0609JW>/LD!VY62^W(W6A6,S<&N06\6Z'[? M!?&4=VS&>C;O.A9\XP7<^DFPGK"%+[@,%62+:9UT3MH:^O5Q[8G&+!XUFXU6 M;7\W?C6:#6KS82FY;"+(2&++?5&NV-N3(+&I"VFW6PT M6O4$IP9L2R19$^M4ZR=K(+F#`(W#!"UR>+\R.^!;S*B:(,H`N"/"K-EM@%#S MY]M.#Z,$S1S.`=P%6Z:FFNW:FMBZEB4PR0.GPH1U[9RSB?"9O<44(0$R-:8N M`5P`\JP9MYKU]F:X+_@3M]T).E6(8X8<8@3N33PA^04?B+[PP9H%XX#T^"+P M(-R9?V,+'I5;G59#8]+N1+SLG+)87^Y43SJMO6DW\$>N)_[D MULK<-]OD5]5_RPB;QU(H09EB5C1!E")NR9T55"C0A5&P48RS$06;E$BV8<1\ M=:0P6K9@R3):M!AJ_P9H#61[(FX-T[,#<<48G5IG0](P`F(GR$W:L5!XDA0* M<\QL.2)0-YOMQGZPYJRR66VVFZTUT=Y..*ZZ,[QV^NZ8_^3* M'=:V;-9J+:V2E`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`L>`%L&($9Y$A:W/L^^2FY=.W'XUNU#T+JK_6@U&VDOMR;*?5":[Y!K)RW] ME/MKDYKK.UJ=YNZDPO@^YY:\\MPQGAO`OL?;@;9_OD,T56LVT\6W?$P%TK6N MDK\L33FK66O66H7P2M/XV6YI5*NZA%'S*(JA)7_[TVS73EZ6FCS;6VVU&EM0 M<\\G;(9Y)\1VQ:U3V6Q7]1._>5B*(6?]LR3[IR1W)VM+QBPQI5?"`3TLRB]$;T[7 M-39W<>ECGUTA6S`ZP.TPK9]*[XYIO;.E.9BPROG(GKG$9^`:"N+A/-A=L&Y0 MFB@4Z[J\S<5ZZPV9(_ZD>XQP]\VUA44?0,SO8$U`ONGC[2!TP,RFA@8*R"Z$ M[-NN##S^"(1]MC&7REF1'[^W_;._EOB'6?F>C2=G M3D].SE[V+^.&^<`!PQT88=8.;#28@U=%.9#"4Q:(3S\'4F"%&&D^[D74'T_P M+Z-`5FA$%HG)J%9J3>$D"._HQBGC.KIRRKCAT_`J+..#/^(&$?*_9J-U%M[$ M$GW1/OMH3)DT!,BF-W$]C.GA@X$OD70ANV[X$[.8X3K&%>]Y`?-F1KMDX)U- M%>,1!H8P#0',-K0.64/UZ8:/2P;@L?@`.$^7>\52;(255R3\`?>JF&=)X[,+ M_Q@?$LJON@^?=;(SWSIW+3$0?5IZ_>7NP[G^;L=LEHC]`MFW2#+=P@)Q;856 M2^QKW>;DHVCHT?SPCP#_^.*JRWA`#3R'4`;QU/8WR04R\(\!:.0B](O+\]O[ M[N/U[%Y@#2#F$TX-88F5L>(T1>^)&CW/'F'B0'WL@W"!Z MS!@2K_N*UT:/20$:.1V)_LC`2\,P3_-'S"=-BQ1H*FR;S#;8*F[XK@%1M2W^ MY(8`1$Q=&(/FS`)K#RH_5`]L;7LD5%W'!7N`H`)/D@KW0HM7,;H2/W>#(4S? MJ)NDQ[52BHP1**KC^H"][PX=:CG#KSUUY*1$).`89DQ=[QM-,[P-P5)M\XCA MNV:CU#CIT&`&#$DZZ5.C6IU2JU%5=B2>*C31.C2/!5H3B;SZ+V,[[P&.TCQ867ES/X*H+?1"ES`K=D(ZVD.F:T-D&W'`" MT+'/(D*UZ4>VZ^1,1C0EHXEY*)ZL[[N>-#PFX),,>KCQ[^/\+3?HX7(.P48B MTB60-0[$0KC(=\V]&SEZ8;DD0^!8[,#B)$#,0IU3CP$'4H$BAL<50LS(G+X- MDIX8<9`#'.19*(6H`@8;TS[=DL&Z-I""C>D:R)Z^.G+D!K:5DJ\>IB2T#.O/ M/K$TVK&=@J.X]&4/`M01)^OXB?>[`Q1]F.T^`S_Z[OKFXO+F\;2LC./:MI^B MGMK:0:'Q$(S'N$BPEMI\=7 M35QY]BC&H`(0"1KW+M@[]66F1]T\T$XY83Q71$Y%E^_W$"[-N_AL0S;GB#+\ MO2#W!B:*\HNI\$?T.936B0N'Y] M,+YTNW=Z\$H>%3P`?P8*P"(2D*^5APK87-MFGDQ%Y2G705?R&3/.P#.AVY-) M1%]K5_;`U?U'N*0&-G.&(:C+F_)Y-QG2^[A"E*GB(<9:.I+8XQ=.7Q=#VY?G M5UZ@7;C"20RM%/O!^086Z<"Z47;A6C>`>"TB)R%".`,,IM&FD5[-%B(;B-E# M&Z&-)2T=N*X/0P&VAX&@IQ+?#'JR"4>"^B[>,.QGVR8BR.,PCE,$ORP6"^.= M'L9;C&8/(<+O@=,G2HEURT+"O$7!*:KI^4@&!$Y(,4*:J`HXQN:69F(Z*MMX M#X9F/=\0R@"D0S!_%$BZOB1DVIDQ0,WFT-NK*7,P44&#"!`TBV\##>\50 M`H!)MF)J*E"&&+84":P[$4X8YZ92&$^/;F$=)LH30TH@/)"S99E$/"4(#822 M6G\Q-42*5*R.'0'D$#%?OCJPW:F,I<`?>9P;8YCV*)0(&8K$'`X" MD-23-$1Z3I0E6PN`D!.@G!$W!,Q>.!;E!T\\TM,(`7"J1WZ4]TG(`4.87?T! M`NOCG<`ATD%@*[_YQF1WRPBR_[8BR*^J2'$)DQJC*7Z7P:-R3'$>NL1>H!5` M)X'9+AG>,,"+/(1>FT#Y'+-O(*$18Y1UD#(83Y124(;+!@,0X%"RL3R!'B5, MDH$2K7"D)\=1(4DEG#A0I;U#Q+SL'87%"@O#_C*[F)B,17*\J`T*!W'5S",- MBZY7U%XB7TBJGBXR>WP80)`+>LV?F!T05Y;SQU/'5*)R@Q5>HT7U[C%8*/8< M%A44+#*!-A@QC"G2<326\+#`YN>A@]?[X<%4K,;(DC$2TG<]@6$WSM43'*,5 M?.\)K),;P#OH/./B#2VHP'J%+8!1D8WRZ!YPJD\$8/B44>H+KQ^,U4\MR-*\ MC5:U1I0U>D(52#)Q(%+(W-\#:QBN5L\-U,+VP]U38@=?)3WX1NBWE/A(?VY5 ME7B&-AEC#[3';((!G!.6X]3TI1MX,<>!%0$Y1S67A&\4/NG)V)A!."9`_'%6 M&+FIL(I<*/[H"(=/>;6T>"4!L9(0_NR3YJ%#)\HCN"$>)$/"BOA3#$;IC90T M^`OTER*?DNW6J.8+*ZR4F%OOV<&$P[M?'V\?[KKGEZ<)"=;;\CAT5WP'&7OW19%^@$67`N\JI:!S)(8C4`A;P'31!$K?"Y0%4-D3RCJ887^F M;'LT`SWT*FBX=H7@!XL[[ACB.@*A1691/!:)&]*+W7;@ M2,,0U"5#0WS"?&OBHC<5M!69$)K&M@#?P+U*]86/<4^`.S;4'3#F_LBUE-UV M'9B*+Y`/L&IA6*>&)>^+03D<"`_5VQ7CV@DY3-B3J:@(*N*0`C6!T(W/IYZP M1$%8=K4X1`?8G1XB7.`K18L84 MXC%&A1Z=Y?R9J@YR&:]#U(*$37C1XN#Q#!@0OU$QKE+SBL6?6Z4P`)IRBMU2 MZ[6XID2U9O>C0$A5IM;3'Q4<174.B;\1-1!#")O>KNE.X(J!$JACIS^3/=&RU&3+51J):\`G"HY^3F@Y MK^@Q5LH,3K_?A+H6EWPIBW\68SS(@<(=*&5W>Y)[3V3(A0/62-&#MF1^9.`L MCIV.(/T8TVQ0*;'0IY*V2L0`3$S@#2%':"FT$1`'@HD#0Z1R6BOR4#8>@Z*P MSHG/592`S-]YGPP,QRX`]+6`TX-T/CY*$))$-A$GJWBXX$8N$?V#[ M@1X?%D/JTQ0.O8_1,>&*CADP=8A@*1-.WZXAVW`#G*3])^*SN<.YJUTIF)M\ M@8>_4OC"B6+90IW:`,1"VY-K!UA, MP*W7`;I,JKY!T"M97X7!'U3E(47&QS-\8^Q:W"Y#S@-/K*2"2Q@50W6K'SG9 M---PBQ6XV\/:L((3;L!2)1&C]!*-<<'E]<+ST;U920>A:,*B./M+ZFK]/T57 MZ]OI:E9X%H88R:Z"2CY=VQW.$N7-"$JT2"3>84GBE/";]^`G-BKT9.]*ZQ5* MJF1">*=K)^XY,#DJ1<H'0!U>XO.(K67'>U%6=$9:[5%-%%W?.A% MR\RT8G%)W,!3M4\ZD:P*`F@FHN`Z*0U%05-<'@KE)3H9'LT2@&X3.52,WWBT M;C]E,AW4P7.?:7,[T?KCAEILG4/>_SN>.LGNO`WWV^ M7>Z])A+7'O-VJ,.'`HL2/ZG6(`+-\.Q^A7MY$5SL%RN6B+FE2MT`3A& M*=(:,TO.L@GU*S;:,74UDZQYX,9SQH$=4*/,?47-&VB_Z[?6^?&YFR62>QX> MM;#L#34'6!T?6;C1+\SVZ5J^T3?E5@U;SP[X--^OT9` M"#<.2+*ZKE1Y_;M&J]2L-L.C#Q2;&.X4D>,^`TP9?"[:),=URB)LSX:),R]N M)\)`QL6]B#%\RE3\#;1XQ:^+WL"TWI#N-UY/]]5E4FI3\:#NH2LS6YU2W6S% M^WR#]"81^G4GWF+#_K]JI=K2MH$PJIV$UT'1<\#3;)K9WFQ=X9S[X>&>_S(" MO'./47/]IBF\_)0:M)/K3Y%].-D=!.9M=$FM@?#6R9=.2(Y\&Y,Q?1]3N]K; M&'`EK=^==,`85TD.(^<#7U,[)X5IV"P/XHJ'\>BH6;B]&^ZS8P<4)67JUH'+ MV[GN(3W1T7^&.E,DTY8XZ$E5';M\0@?VZI;W1$^4$^H,15Z16Y5_`;,*:3E% M]M&158O:6B??`/MDXD'7<]'IMSJ5\EO!W&_X-L)/`^-E8?&RD-C MY:&Q\M!8^98;*Q/7D_8CZ]RTC;NEL[=1-CYT7!XZ+M?IN%QYF7M:IG-_9/&- MR?^A-_/0FWGHS3ST9AYZ,U^Y-W/Y[^3F>1?LS*/&/.TZ5*VW3KWZ=GS,JW=Q M'GHW#[V;A][-0^_FN^W=W*NS$-7YCM7S-?HRMR_8AY: M,`\MF(<6S+]F"V92(E@K[4\??^Z/N!78\`+DU5KO6JJ]#BO;X)2'7%X[^ICH M1-`;K%H?&DWF_PHV$7XFV#_W]R5["8,`]$S7])3L)VU M02D2A59"E0"IA]Y+TA:I!400E+_O.&,[#C0K0LF-)+,]KT,RUJM/5NOYGBT8 MIBC8_.X%@B9QQ3\4P0;Q$SWWWVP$AQ^.Q'T?+_N?F0,;3%VAO2IEC M4FI#JZ=J:)-H1H.M8CF'"VB/W7X"4V3(JU,-:AD4QDYZ%Z6B=:C)W!L6XR9# M)1&0U&A`!,0+N-!:#&)L!2=/^.$_#B)@U&"P7LA[M1"TUE,9!*(/FB$P3;\# M"$S#])L@X)/&[=:D<6\X:3CYN9M2KK<.EU6`RZZ#:W4+;NF2>"5MVJK#ZNW?O+]/PE?I'\H+MYA#K'<)"#R.E'G*EE=GCMD%5?QQC:9 M-X`GY=I:]H56DLHHV3M<;B;+GO!>N9^>\'2FF!B;I"50Y^;^P2LMG6L%)(U2 MH0K([_ON&W[\`5!+`P04````"``@,%9!6^L/Q]X#``#4'@``%0`<`'!H87(M M,C`Q,C`X,S%?8V%L+GAM;%54"0`#7!F%4%P9A5!U>`L``00E#@``!#D!``#= M64MOVS@0/J=`_X/6/>@DR[);(#'B+=P\B@#>)HBWP-X*6AK91"G2RZ%LY]^7 M5*2$CB79[J:0MAZX#/!01Y?.12U%X MIZ\P7$!2,R1<=SZ#5EX$Q3JJ"PX;SO]@=!X#B>9S08 MY=^'YF=&$!SMB^.HLU!J.?3]]7K=W(>6;)"_K> M(.AN,+*`QI1MN5DNB$P(Y2M`I9/)88W=4"3:9M#OG0X"2]48/S(K.RIY7H*S MLS,_V[6EM;E(/8G;UC_XCYLOI&D-G*=<:WY/'@F6@L$]Q(ZY?KV_.2H/OE'R M:22_70@>`4>(/A%F'$P7``H[3A;.4#TL8=1!FBP9%&L+"?&H8SQXA3G#RKL: M:_XSZI"P,&59@4ST_98?V"C0^E'AR8!\W;`,CAP($Z'MW&6F;(5T[2A=F[R8 MX"PC)$5O3LC2>`U\8`J+%9./P.L%>9V^RY>_C1&U\\(R(S-@(_?%IM\,M`N" MBPI@V98-RZ)N++<1$AD65O2?&6]N92WG$CZF29)9\_0H2PK]6(ID)SN%,_$" MGI.B]B26Q@IAKB-D!#*?J&N@\X5ZO&DHNQ-*9I111:&*?5NB(9#C,!0I5WA' M'LB,P9A'>D6F$%G8+E(I@:NJ$C["0M,%54*)755'):/=Q7>9PM_B'G1^(;HC M\A_UCHURM1835QF6S MN$5RNWOK8*)^$VK*I(YIK'._[/#WR\ZR4Z4G0:+;'V_CVR7(S.-_/]16F&WP M=%N!J)FFN),BIFHBL.JP8PDTU+>?=7K1``"\Y5<;D^:4XL)D\#:^A%G5HW&_ M7M-=O9M\NW\/B+O=`SKS4?>0\VT5";?P%E\.EV6%'-YJ>'KYJ'&WY-.>&AIFT&9N`W9;TT5Z_RV2;?,#_FGZ1ZY0=0 M2P,$%`````@`(#!606S;TM!:"@``L9H``!4`'`!P:&%R+3(P,3(P.#,Q7V1E M9BYX;6Q55`D``UP9A5!<&850=7@+``$$)0X```0Y`0``[5U;<^(X%G[NJ9K_ MP/0\L%O5A)!,=M.IR4Z10+JHRC14R%S>IH1]`&T;B9%D$O;7KV1P8K!DBULL MIWC)Q4A'WSF?=(YT9(F??WF>!)49,(XIN:XV3DZK%2`>]3$975GI9.SMMG)U4GIZ> M3L`?(1:)/?'HI%*KJ;8#3+Y=J1\#Q*$B41-^_7$LQ/2J7E>5G@U\\;),_<30(2%@)/7-FE MK@QV>GG>2%15PC>T2JK*TBZ-SY\_UZ-/DZ6E.%^\%$]*OZ@O/EPKC3/@O-A: M\OMA03!B'J,!/,"PLOSSMX=.NCU,1-W'D_JR3!T%P<=*!/9*S*=P_9'CR32` M^-F8P="((P:N"+E05/RHI-5WQC260)@7#J`FGP)1`VR/&'72=\?\(JOFPQ"% M@=@CXK3LO>*E:H@K=JKQ<(CV-:R$QK)KH,)5D_OY;\KC<*S M`.*#'S>K\!]2XPA478-JW_:_I5(MPL&_08%RE_TQ@.#;6MP@[!_>U8$&0FYQ+:IL#+ACR MA`'N6J$DU-<.V62KH*5GC<4MG>PJYEPO'-<>,CK)-%W<+#4BKH1MN>%6?; M>XP&.)#&@CQWH2M9`I^A5=!E&FY#QM0,R)J-]0J%DI+1GPRLI/1US_]X'@V) MX#TT5_,0.3>53U@(?EH+DY/:0((K]!GZX8I7V\0PSM':"N&1/D`@O8C?0RR? MQ8P*)2(M2VV7_6*^(RP3"RN*Z\H"$WK9UW)@J=L>?TJR8I64>?"R"V=3"C)Y2)5 MK$1$I%5T;E`T?1\OT/00]COD%DVQ4-#T\S%#Z1)Q8E38N6#2@AD$=*I6:G+) M-H(V$<"F#'-H21-[6,A)8S@)HPE)*V28C-9KF.9CNPLN$>'[,*.^;_SDTD3# M>H)1)NYT:NJYN'!BKBU7IK?8]EB?GT MY$*6CG8TKSPJOLJA]%$LQ*L%[SU)M>I$M48!/90L.>-N#79CFS+ MK:$Z;M*]OTVZU>6-)+S+(G!^-,?N`>O+/F2WM#-6+D&"WM8,SBW\5H%'*'DS M%&/*\/_`M^(M5:ET?*75=FYIJ`/ MS,AD*EU&6K)CTK\=HB0_(&56*2,Y%J'H\ICZ.%#JXP4\[PZ[4V"+@SP[9ST, M8HM+>!@`'7,=[R_7\0`S(*'Q)8Z7CTO@*U]5<2XCL1Q$9-1^GJH1EO=*I[E\ M"7C(4':/*8BT3QWB0+DP'@:J\3M(=6I-@4+-F=LKE%5U6CG7O[\`D:H$ZCU# M?R*-J-00>`9+Q0R]/*^6^^18Z^]@[HT.@?,(CV:H&(N5AY.TALXEV5[TZ1`Y M(X-[RDT\Z$J6APJMGL[ET;IB#&R!,"\\:TJ6(3#K%'1N4'R1RG+51>1BE[2? M5;<),1\K[;K#%@Q,I.37*W;`F'O72B3)U]ZYZ*\\+189WBM1H`3#)*F.T;Q+$GYQTM'(3"F)[,JU4"5G(5WV."7[^V^`/4+2W@-V8=F);N:_2?H[Y&5YT?3DHMOFR/06@ASVQ;N8Q[G)I%0B=S6\6J90 M9K;ODFO,Y2^-BSQH[?\WY"+RL>J(JHQX'@Y@!?4CW<_0/$A3[Z"+'(:"@R?D MU7JV2^ZDZ?`,"'`9H\U'ARTJ%'N=R`&'03RISC.8<[Y!ZLX`J<-.B]\);9=' MWW)&_`8"WL$XWL15-S.2<5S>`O\,$R0G.[LOJ+$'E759GFL>Y<2S1>P`^ MOY,&4"_XJ@.-W6'B]5+SUDU./1?G9!9==VW')\\XSH7@).9$,)EG[)!F5GEG M-*9-XMR0?(`IFB_SUI8,9E9Y!PQFFZ3$@7/G@/D>V-W$7,YMO"OD\ MJR8M:Y>`0&M#.'=LM:,N'P,NU-USQLQ;HDBQ9&S6WU;3:DD]G5N=+3:$'M$S M<(50SGS,:=#U@N6E)*VSW:+K^,;7KM]+A+D74!XR^(J$_)D\MJD"D<2+R3*M M<1-RK/85M_Z>HFW:>OOO+=H&90%\]%I(@>#;`G MUT.[%Y`)Y,&(JP/*)%.SNQDX**]"^ M21@%F%3S?HG*KNUN7I/@`DUM@E2(GQ]P^#N4LX3V3"T&]^'1UR06ZKO7L!1@ MX72LZ'7O.[>==G]W6V?(+M#J&:C>S/Y?J-H@IW(>Q4BK_=CLW&]M;IVH-[>N M#L3Q*(%+1PGTR=_D'>N+6]342:U]ICL,!QTH^S;ZVLOBW:!>.OW MC&<6==RN9A6/&8LWB1O)54;3GZF%.-\Q?F2)?/,XD@7F&$_F=TEB+C6^ M,+>*XSXQ7^6#1Q[3^Q\95L^MXKC5\U4^^!F=^`H7E;6_F3>3*#0&SRKMN*TS M%3U^C\B;!_ZO5.PUZJ_(*S3DKR`YQGN7XOV>7OU3!"]/[6C/PH[O52"K@YH\4AJ.+=9R_N!DNO6<6#KY)Z#'LOWR=B9^7<*HY;.U_E MXZ+I3>)W:@M[QRANE/?FL=R(Y!C1W8_HB;O^UF];[H,0@=8I6E1RW"W:J'WP M8*_&BMG(R4\=M^:*(L?=-U,\63Y7/P:(@WSR?U!+`P04````"``@,%9!SD?_ MY+<;``#!(0$`%0`<`'!H87(M,C`Q,C`X,S%?;&%B+GAM;%54"0`#7!F%4%P9 MA5!U>`L``00E#@``!#D!``#E7>N3VS:2_YRMVO\!E]TZVU7S3"HI>S;9+7D> MV:G,>>8\D^Q=75VE(!*2L*9(A2!'HUS=_W[=`"E1?`$4((K.?;`M2T!WH_'# MJ]'=^.YO+_.`/+-8\"C\_M7YR=DKPD(O\GDX_?X5%]'QV[??O#L^?_6WO_[Q M#]_]R_$Q>8@C/_683\8K7WYAGQU=O;V^*NS\Z].R'*Y/&'^E,:2 M[(D7S/CI`O\:4\$(2!V*[[^<)G0.SKT[S@ MEW_\PQ=?R,(7+X)O55A^G1<_/_V/?[M[]&9L3H]Y*!(47U44_$+([^\B3S;` M@"5I+('_.\Z+'>-7Q^=?'7]]?O(B_(*@$QYLL5G,:#RG/'QF(H%N"=E2H%Y. M46%G;[\^+U1%XAVU4JF2Z>7\W;MWI_+78FD@YR?KXD7JWYRJ'TNE>8LX:UU# M_W[Q71P%[".;$,GS(EDMV/=?"CY?!.S+[+M9S";UY((X/L7ZIR&;TH3YJ-QW MJ-SS;U&Y?\J^OJ-C%GQ)L.1/'V\;)7NW14M5.NU+Q@<6\\B_#G<3ME2[9ZD? M$QHG%G(7ZOX=1VG,]CLITP^?WRD042$P"& MU8**)90'8C0624R])*G&Z'*S1C%'HEBG\79 MXEUL%8V]_`OXJ!$N*W'J13`C+Y+C7$Y9?1)'G1V=G3(C%.'"[(-T=? M?WM^=';^C?SIFZ/SM^='W[Y[N\WBB,!?"^8E_)D%JZ$AM:D;RF!M!T!_>+WC M=,P#GG`F+M,X9F'2L%X:5+#&L%X8*S0KDJ3`96CHT2N@C"/3[MA]7_4011F+)C%\DE(3H9< M.@<82,-#38)'WHR"`"9K.HQ3&0\P\!G.IM,V(="RXSVF\`NP3]FO*85NI MC`B,R4T"H]ZL52E8442!#]7DCD+]!I`,!:`2A#H9RJCKHOKBSK0;O/N;R]$8 MY:>A[T+Z^I#'(7PT6,("S$*_]! MR$\-\[]C)M9KQGX:;7SVC.WLK8Z5`%ALJ8L9Q*M!:E7P77[X=O0"U*?">+)XY,'&]^0S-#^0`59 MLB#`?WTVQV]\MH@$3S(KQYB&GP3N=B<\I+!`T8#@W11/4GEI>4)N$T(#$:&E M3;&(8#\;]3E=Y;\3ZOL<90%BDQ290E$:KDC"YTR:6*1X;#+)K2FR-C;. MC^FRI@[^%*4)64`OQ&ANQE,2?%HPX)&L3HB$`QX;GFF`0^B(L!=L/&*#)VP. M:@ZH$'S"F53PG,:?6$+'`9P3&/2`/,@>Y1J#@@OD1F?'I#"0,.%#W MLS.)W#0H%>"!9`P*AN,,]3D4A`GBF<4)1]I)1#Z%T3+,CCQ2EQZ(>B2U`#H( M&97V3QZ#2`G*L5IK=@7-E8LCF?.0ST&9T".?)`FU5\%N4,:N,?-H*ECI-QY" M"T!:$M.$`2Y^4!T^$W.`1\(7B]=21TC=5D"D<((<+1ET-'2EAC1R!SA/(SC_@D*A#/87 MVL!IF2Q9SACT&_1'S/`2'36QEH:++5E/I,L"@].MW.N/:8"WTX#'&`%00*@? M29X!FV+?HQ4S@8.D&KSYF(,.`06G@DY9CM$U9G%LCAG46\"@4,-'#C?4L/QP M71QWRQD'X)>9L<+D,6.!).+5B(]ZHCB;01_'<;3$GXHM.L+A)1='@8@!>..0 M!`@I_.(\!V6@*4@RE:)]9RXLA& MQ4WS8;.E`B]70149FZF]J0P0$!',W$A+2K(9`?]*@?U?A&PG#U.YN"V`?S:W M7[_L1-OG`LA"+T_C*%V0UW(VYR)C@L:3G,>;09E)6I?AHFW$8._2WS;\!X0P MW@8Q<1]>OR#`4RYF",/[R14;-^W']?6L-^;&HMELSI`);F=^3FP\;$&A8V1J& MW82TLZAGG-1UXI&\(D13L62G]D]#`V4W[921N4L?=H4G;)I/IM'SJ<^X0B9\ M*`,2OOI%'0Y^C@+82=!X=0-[@[CLO-!<;F>8:5G;("H[\*PI$T5Z*"#2MCW' MBZ'>=[<[_!#!I'B)DL:AWBFJK;25#<)`#*O%#LF3C/X0G:`,VE_<21GW0W]+ MV@WEL9R\[BZP^*MYE-Y8'RL@FUMH@UL.H8VN`GIP?[(#XX?[NZQI;AT:S>@W@O MF;LM[<5?R>5*=G<[>G][=_MT>_TX-&"TM+C%,^G0ZQ8:)1IP(7^R=[XL,+"] M31E:EQ?;5O%BK&AOOP>8CVS*$4IA\H'.RQW26,S!\:6>L8/3RX8P0=[IUEX\P:>8SYX@:D+@:89.&G99.(415+9U8S@>Q,;XJ'NE6+ MMT*&:,;'G2NKN_:8N++*6Q<>3H)HJ9I'21"%4WEG7+B[FE.?59N/]ZK+&4-7 MUI!E"O%H2-@+BSTNF+KDBN2=G.#3D$^XAS,U\DL9WO)%SRR&H:DN]B6!OV27 MU_+&;`(JP1L@O`M;ABR6U[81?.OA9QS2ZLZ9S^?,QX)D0N=0!2O@G1S>D,%Y M2^"%6W93#4,CF9V040`M#+&&1Q>HGPNRW7C^S*Z;^77LPB@>Z0@\'F-_@FSAE?F%KW'AVW8F8@U.N32-L)JF<#XPB MR4@Y#BA6)-CP(O]S_K\N)JO^6IRL(WXMFCV44>M&;55;@CW<#W6S)V]QQ/TF MCLWH2J]:R_%=7J-83B_QLJB_0A3?T(!JJ)7VRSM-;^WKT)OOC-?Y&:Y@M:LY M]=:7LSKVMK)VW6A8+V"[2"NB^09 MDA\I,G2]R=Q3PUIWELVM&\H(L]!.>;G>&:;]C<7[>$I#_ILT9ER":%'`?67C M"OUB]%7AMO5Q[31K/F"=L[$>U?MJN%4"%'3FEB[6]VNG7N5(K3QQI0LW_/H^ M%5RZ33J>$`ZID]99HZMBAC:7[$NQY0EGO\.L5ZM5-&=/](4)O,C_P)HNT&L* MNK`V-3"W\ZR001T)?1FH;T53HVNL(JTJ[]/B$4UXTI+PJE#`@1VCS,PVU56& MB-=(\\W0\%!M;M464:_<@V2U4J:0VM0ONM(N'J)+HV:^FSO!PXQ52= M%EHR337WQKXL6%E.HAM8\&CPGXS&S4:LQJ)6=BR=`"X22BGB!*D/TIRETT'1 MHF76"_N"RPBV1SYND6X"6K:C5W^W`D8M*ZL+K)P@08I#ZO_:IA8[O46MNYLO M;S9!9RH02V_$U%:Q,F6:"F3E%;X=:8=R*6'B<8&3SK*8C84O'56 M2HW)M4N'6<3F4Q[>AUMGJV;O8(,*=A'Z1L+L(2.-H:/K8=JBVPB/\C3:69HX MD65ZFDQ8+(,$QBQ9,J:R84\H+[R,(%_E88 M4_>0+.&?S,B'R;0P!]=6XIM!^?B;=<16YH,.$#^`G>'Z!4,SM!''S>7=V1R: M1+$9HFOB)*?NW/G!A?BM7@S5-@QE1!CKH-%RT@ZG@]P)=DQN95+3Y5WA/M-: M;=\;?@8YK3KHI>4F<0C9K"X99J`,;D.?O?S(RGEGFLNY.-#5LW9QDE.4B21- M@/90\*-M?,W9K4WQNV^9BS8&976HV2;7%++:&C MK;1)W=B`MU.IIJ&/*0+X.,7V,AICCE`9$INU?5#[UF8%%O>J.ISU:1@>)^9N MPDVE'9AP6\5P<7BLNV1UO$5UT(K6#6I+4X8R!@Q54341&P#KD%'95RE[B@KQ M`IN7TQJ&2B<2>XC`U@MLM>_(#WGH*XM/@&WEAQ@:&'?1CC[8V+0_#PG;]?GO MDBYX0@.-]:$#@3U`5B>LU8EK\[!"M#[F4R%8H@(5"K;$B^'#5Z&-XT2RN`RZHP> M7]K&5[^S!!"UL_,H]#^`$EI7[XY$[-_JWDEH%V&LQ3?@LVPB0\/C;LJI//1M MT:6[FQT^LORFYGYBF#I,6\7*)&$JD!VVUM=3<#S9;^HPE^TQ3AT6I8G*'1;% MQ=LX^3R7)I,8+>GC=Y1)+.]SU,IGD4C,%#M%TTVWT=GCXY$;?!3>0,5LV]S@ M>5ZSRO8/2W82TF8*>DSG<_D>]804F&X]KYNQ=6T$4.',O)V4U3E MV.7DT"N?/Q&K0UR$05;9Y=[9USP/!:?3:YUBKN M`VT=YY&KC;8=&_BFSA.^J:237((-[&V0L,XF6(S!EM2'@@X#!=1E M%&SM@-V-&-E,5/1DKDWET%[6RFRA%<'JL)`M)1-\>!:7&"%3"^H3.?3>`JV% M(DH`SV$Z'[.XV)YU`]&ZH'R&-L^'C]'-6$2!C]:!*3[&P.2SNK(6/NF,QH+7 MZ_?(MVE*,DNT82AU':$CQ_H-930:J,>0U:OCC"39:\MO3LC3C`F6TUD[0N=6 M\>P!:2:O%Z43-(_GN5/(EFC(1)DWE)4B>_*8!M)P(A_+ID0ZEX#8F;?)1D49 M?YHFLRCFOS'_A#P6$WD4GA4O;SB4341]+=]%+K5Q4,8.+?Z*5@[#4=RC>2-= M+`*9!XL&^'[,31`M]:]Z=*UM;^#H)J:=A6/#BFQ\)P:SA.VHDLHY?Y>NVWVI M^P?CTQE,.J-G%M,IJ^S!WU/!O5'H7_$`_=%J%L"N%*R6Q1W%M<%=SI)D///9 MLL"52+9R=LP8NUI$]]A>$^,_S9I<63U@G4E##*G)U@RY)!44(E=)?)(^%7)% M@44N\*0?)/PX7FO+5V*3ZX?'0:T=.ZJ]N*)8#8L>UQE/?[^^NKC\^DJOKF]O+VZ>A@,Y<`Y7UPK`_=E\B"J#% M''M,".G\@.D='EF2!+6K@D$EJX7`7"BK**_"E+8HL)')1XA0C%S-]6Z;I)O> MK9O6]YQLKI[B--P5AQ:/\+%QTO;87O%GNT?U:ACMR6%\2/U?U^RM!_(:%=RG M5]\_4Y'(VW)TE<46\8!]8,DFD=-3A+MZP.(S]YG_?O43;)`*[HDC+^'/)D_U M[H65`W_"_2G`SAEQ+1=:>N)<,A+F&<3@6^GJDF]8"UZS:XF&,ASZT';5ZW'? M>.O[@J?U8L?5A8X+\"HCIZ(W.`ANM;+^&J?/<-<;`&5\21,VC>+F8-?M4@Y" M76O9.@ATE71)3G@HG:]I=S7&M47?%J:K*/ZT<>A7<84L],J]WEK4SABE$<#* MZJ1HKR\'_#5U9Z8E!]+K#AG7+UXU=PWN-;-(E+;%%LI@21]0,RS;D$9O6T8@ M(]SUZ$(#Z_,H]/$?M!4\TP#7<^E%MM+Y3)K5M7>JZ2*BE7<-[O;0""FW?6S# M:RA@VTDC%?^:[KWVF3SVI$LLY(3V89]UCA="_G^9P?^E:\_DGM.MZ0-55FM5]V(?$1VOOI4:L MM%;:RS/B5:'L<%3_BOC&<6MXP#+1B9OVF:5IOSF9@+JZR]O$W@UP_]X]\Y++/$OUEO,\FQ7F+WF_&A4#_&J, MYVVEK>SG!F(XS=E%S>,T#]`,O2U]]^;T;2,W4$G13&Z,L/[F42-?2-?^C^Y] M'HLAI$,!2'MKR[.AK4^C&S@T9<%HB6]OK6(-%1.!'*6T*:VQ@YEHNJBBC"KS MSCFX';?&?Z:;';>.P+[LN"W".K'C2M/M;4@V3Q=\=I;;%A496FZU'=KC,IFE MI\XSV[>'"YG6LE](S<2RA20ZO>$+CBHDJ%L4T$%67#.U5);@+MW5HQ>?2H.3 MY[@#@>";.&5^P9C3?O;M0L'>'["[N%8>KQF[/,FAQ"55'$U?DCJ(0V%W-56\ M#G?MUC[M>MGM\1T/V2U\;%K3:PHZL.LU,;<*K\JIDO]"ND02_N^AP:NY[56; M7KOF^TE#\B#?!S9+1%(LZS`528T(+I.1*/)#3T=2HX3FA"2-';'GIW[,$V09 M5G+Q"-">DV3E+P)MY4Y,/7JK(_#`*8^8S-I>;P*U&OX9: M6U\4"@J0`?/(J$RO$X*0;/0)F7^`A^MTP3"9 MRE8L>3+C69.S.SN59D<42 M0*KF@J&@K*-:=,:!@;B6_WM*XX3%P6KML%M(HJ.#H&%E:R1V$](&D+ M=U&-852D06<>*NQ!GNT:H%E7TG&`PQ9[AU$-9./I?T'.SX[.SN0?LE@7RZ(> M\-".66W71W^82/]\=G)V=BY/5+(4N:U-1GA!0AY4*`X-UBWZ;H^8J.GO_9J9 M_\&"X,HA4;2TY^1I[OK_% M]2?![B?7(N%S?*2M85TM%;)>4NN9VF`5*.)"N*8Y%!"TM[B\GK7IV>8ERH); MYR9=>$N*1ET-RWW:SNGLZ1#2):9].YQHWW)//H<&GM<]Z,A101Y&VR_G5KSW#. MP0TZ,3L`M\*OSV"+9Q:FCXBAWKEY=LZ9A7!KY>90?=2AW:]B<,AV MJ%I]/+7M]>/+:<;@TI6!QQSH1R$-6P]:/TZ9_1F*"#IIH_B4:=K+QUTH8X2 MMIGYM*X,QO7WL>BVB^HJQ-JYE\,^&M+J]3#D@/'.VC!8UDT@>/`0X)I4?9J] M[PZ$>DSMZ')!^'WE<-1M3&W[MPW%O@)R):ZJO*SDXC?(B,G0;Y(<"@]W=30ND#>JDK=W$2/_&?,M"^N M6$)Y8'H;W53+V8VT1BQWM](T8T0R3D/!1D>%--U.&W74P<^3W5\;W(%0CRFF MG.[P?U>9I78\3P[PS;Y*X+LV!7Q;#7O'"KTXKHR*GT'F=P-M5#P03'OGL`\- MU&8^,*BPEP<&W&5!:'I<0)\'X?"^\76Z,'E4H-@SQ1;>P2?X+O\*_AI3P>"; M_P-02P,$%`````@`(#!602PST8_9#0``\-,``!4`'`!P:&%R+3(P,3(P.#,Q M7W!R92YX;6Q55`D``UP9A5!<&850=7@+``$$)0X```0Y`0``[5U;<^.V%7Y. M9O(?U,V#VYG(LG>3=G'>=190D)1C#\F'(T3C M[MNW/[SKGA[]],]OOO[Q+]UNYX;$81K`L#->=2XO?N[?TA0EL$/C27(/"/RN MTP^7`'.!\WB^2!-(.@.,XR5(V!/H=^R?X/@[]MUB1=!TEG3^>OZWSNN3D[?= MUR>GKX\[]_?WQS"<`I)5>QS$\TZWRY\=(?SY/?\Q!A1VF-:8?G@U2Y+%^UZ/ M%WH8D^@X)M,>J^Q-;R/XZINOO_HJ$W[_0%&IP/V;C?AI[S__NAX%,S@'781I MPM7/"U+TGF:?7\=!9H#!(SM2"?Y?=R/6Y1]U3U]WWYP>/]"PH.@$1:7'+&:` MS`'"2T@31@N&]Y3CTN.`G;Q]10O MUOY#+_^R(HT4ZCQBS?C]*B>8Q!&\A9,.__WK[:`1#CU>J(="\NDB#M(YQ,GF M=Q^'ESA!R6J`)S&K@S/YJI,9]SY9+>"'5Q3-%Q'=U,YY^A; MX[I[3Q8M"*1,+/O\FGU0>BQ\2"`.8;AY,+=@GS9SM=9Z17%05.4HXAX>DZ,B M!$=U")AS?E(]HC^F"0%!LJDG`F,8?3@R+M9KJF+1%2D,CJ?QLA="Q!$ZY7]P M]4^[)Z?K=O8M^^A3_OA;.$7\J3CY".:PHK!4K*A@D=L^*2L+2+"IDOV9$7LD M;0EKB=Z"15"<=(,9BL)-Z0F)YPT`W"@1*VSHI)1I$R]X01`==6(20I)'_X/@ MOS'DCE4KP+WTM6=XETT3X_SZT#C?0()B9D-X`1(5X&4Y3Y&O&"NFX,VA*.@S ME4*NUE4$I@+HR]][!GG%.#'4WQ\*ZESM4JXH5>(!B#Z+P1$'G.DHIX1(3=9S,7?#]P3O!7?PD5,^$1KQ'!,J;R!B,6]I$-FNIB7=X?EY;>,#':=A+X/&:S M(DQA>`8BGF4>S2!,Z+9I7TEM%A*]$DUV\?0)H./,:5+:G0*PR-T=1@G=?%+U M^_7'G_A@`6;Y+C".JM,\B=!.C;(%51DY<,#^K+9/A:"EQJE&F3=%E7%[2O)N MST"?4N:IDA4"B9`KR->B4!#$*4[H#5CQ\0$;QK-/2`K#NA6R4-6@!G<(E/AB*;8U@<8Y8B]2>!?? MPHA%DO`&$#V/B@)>T:8RW.7HJ`^'?O%0,FU/*^F[S.CBX/,LCI@>]/*/%"4K M3;>D*.`.+2H^5!8[URYN6%V0N5B8:?T;B%)9@D`D:7WXIO.M(B]"4YWK3@J+ MH"HV:F)>45$WTKF&T0]#E&MS`U`XP.=@@1*NFGAL)I'VBA6IR5M`+FG M'65M#CF,AQI^L212N)*Z1<&X6\[*.:YN!\FR7^=F09'J'F;_=0)(YH-%<7UK8 M%:9J3B:?]LN!<)S!/%[TTV06$_0G#(V8JQ7RD+&ZX<[E"D0*9UL0F["T+N`M M0QN#G4L6B)25'[`P+>4M3P:'*BS.W0N9P89]EDE)+T@S@L"Y:7[M\(ZVJU*5 M\(THTTYJYX-E+1*D[*%DTGX2H^Z;=CY#UB(I^H[)Q7-_.])CT"6]M94/>S2) M#B?#!23Y%3D[I\(DU=K,@DE4\C/7\Y+K^()R';=P"7$JW=GS^+4K:"NCXY,Q MSN&\C@IX>OFPX"%#EVN6RWO!A,)<>0JBL]C,N:YS,*3J9KHFD%"8238G57SQ M$XOG-(VXVE>PUB0$`I:IT/H49T1DEW.MXV>(F2D1W[X:SA'.[G)*T!*N#9.T M$5TI'^@Q1L#!S%T\@91F^@B:BU3,)U;J-CJ7HGNT9X#9(!5>QU3&A$C2)S*$ MECJ7A-+*B0HR!4&E=WB-@"YR+)V%EV6L'O4LG&0_)+28U10/EOE<=HBO M&&QH"3&D;.`A/\]N4,#V;3=[;`J;P;0.,N?B`[.=0,#/W>6_"]:NSV%J6GV# M"IY%6VX"F',)[[KR)I>@&#-O5)EE+VCN\&KVS0"4MWOO,KQU"!I?1=.HBF?F M+UY=7V,>,G>>LOG- M,0#XQF1^]'@X*6R*E2_^:,JY.:XS<-_*FI$.'N<&[T6="UW*2K'.JBSR[(BL M@^)18-\'OPV`=6@45FGJ6H(@WSW2\,DT6+SFE.KB:)1NEA$&3@@VFQ8 MT+\-NFEI+QS`&`KGCN\.^,U\D";\:D9I-J\@8IN.9CY73M45+75NKI7*T*^DQ*W6K-%.Y`^\^>KLSZ"!+VLWAXEMJ` MISNUN+/'CD':7S M.2"KX62$IAA-4`!PLEZ/957<,*@"!%N(NH;/L1IQ#76T^A::@B*ZO63R`K9F M,RI8=='.L+#M#5):EDIS&D-`GD^X*6:B[PC`E"&SRZTL!C5;#2E2K=K)T942 M^]J+A$U*6%O"$>-D/AIJ4H.E(-&`L?)*3@-LGD^H**P;[QX=BI59#0A%12P= MGC1YE9/B]4UV[U*/$V@>$\S+6QXV;//"""D4SR<$"+:"\^7KW<.!K&*KH4&F M5#M#!5Z58EQ0^MK:NX'&B7GCEDE;[-Q%&)??V2,Q\/DTV5$ZIO"/E#WLX&5X/S@>7H]TC@:)NJS%!H5<[?;?\`8H>W:"0I=;/K\-@@YLG!26MOBYG ML6\WYZ#8Y@6F.KT><*2C.;8;^E<+AY)(% M+Z:J=+-L1<@[=JI&.K>=6;*7DYNXTC4IL[+><68(B7,;,*LW;IF1J"OE'7U: M&)Q[K\D50/DK^@KK^@/,+$SG3YXGH<^LK'8:^DEFNP_QSCG:!EGSRI8#34U_COGQ MXYCI3_#%Y5U_<+WU3%14E86)ITB-EFZK*=8,$X`BU5*R2MKV377NOV?6$.^7 M=\=^(1<%2C,_Z3S-UO\OX(2%F-WCONLNLO%+AKBSB/N][H MO5]XNGF3#C]J>+;J%[400*Z2=AYMI:F:%0D+8RV^7[#-@5:I/LNCK)(N[0^Q M\NH;C:^$16SWZOX-KE3(OXRLOI"154LW3'%76E\Q*[P\M(_#CS$.E->N-JS$ M%>:$?=BVP&B8/=C+:QX/4NS8J0EJLO*2FIH6+=WC5*A8VX4IA&T'3C\Z+SW: M+]W6%])MB9OC^N5@Q6M1^5VIPA>ER65=P58Z.5*8N7>(USL<3!"6BCH/L-S( MO<_Q;P@*X&8?D!G.VB+.XZTWVHTI?^W\V(ZC(VE]%L9(4EW:\>MZ]=KQDK:( M[7[;CU&3*?(O8ZNQ4>*4J?S\Q\Y;L45<0TA%,DDC8]1@4<@5M:>=C8OC> MT>?M4@YS\5OG\2R9LO6VB/4W_,<84,@^^3]02P,$%`````@`(#!60?M35WPR M!P``9C@``!$`'`!P:&%R+3(P,3(P.#,Q+GAS9%54"0`#7!F%4%P9A5!U>`L` M`00E#@``!#D!``#M6MMNVS@0?>X"^P_M MH"7*)BJ1*DDY\=_O4!=;MJ[.'0N_))(XFA,A*6<]H]-J M&X@PFSN437L&E=P\.CH\-CO&UR^__];]PS312'`GM(F#)@MT<7[5OY4A501) M[JH[+,A'U'?FF&F!,^X'H2("#1CC$;)?(?:H2XD#P^01GS"U)I!I5EA,B;K!/I$!MLF6 M_4=VK^G<';2XF()(NV/]^]?U.!J.U,%[C[*?1>*=X^-C*VI-17.2T?@ET`>6 M;IY@29;(T$HKY"F32M.=E7?4.CF)\*$5-Z:BH32G&`=+61?+222;-!00R4*_ MV!9'"4LM`F*!!!'4-F#*O.MBF'@JFGCZ%=Z#@#*71R_ONMK5D]3?6^*B:)Q. M-$QO3U(_\,A>\FTFB-O;T[29*4<_`D%:8%4J(K@':J7CI)LM4)$P92*+KE<= MIQ!8V#F4'(\`P@,B%"5R2=:>]30N.<3=UB50H8R^58<\/-G6(5`AWEOTQ<;> MMKZ`BAUZSSS=-,8W\`'IA[]O!VMX=9DNMI,ZX@?DT2F=$T:D'+KG9*+.+[[U M!]?C/42=WEZE1&Q-8LYJ0GYI0Z[\W$8F&D/(1 MM6$E-!I>#\X&%^.B+%HA754*]W-9]E(^A4`9KQUHQ:U<@2`$H1="#6O4]D#C&\",XGM:*-:5)E*9:O"YRA7B]+3C@@'98%V=&VS M`Z[;\U;2LM]TE[OCI"Z$KD!^R'+'M$415"9:E>O:N0#2*`C6"P5GNCNVZD]R MDU]JJP]S-X6J&/JS[#PWSG`X@=J5I0<=%:T.3VO.BC*"59DOQU;98=$*;\=7 M_79W(LFO$%R_F.OQ*][8;LA4Q52G8`N;JJ-8___#2M?*_$0/+VN_WW>I'W"A M4'P3Y)K;44O%W03]9J87%$S]R>SLFP>=UKUT#,0*KV:4W&ZPMC5@\T*"[OY8 M=]_YU*C[W(6&1UC`V#,?+`AF:L?VH##LJX+[XHTZ2U2++P]8A%/R?2+ MN;I/4F9"Y164QJ9L7D;2#PTZK[S(%'>>W#E"C'H>GGB@JT2H[][H6SHGD*8I M=W0P]0PGC%.V@:+[!48L(96`1#:`W*ZE#)V;#)=Z/ZK.!/H3T()]B8%P\I3V MJEWH&+TYU"#I["AT6+#4.F\I"_IG6)) M;1CZ<^J%BCBI#UNKO8R3&]-O:=)A.3LE4\H8 MC,70'450R[E7W/B4T6,+XCR-)P6;N&N*)]2C^KI0ZE*=U)N:>7KKN.4T6U=Y M67/+?VS@XH`I[L:F$V8MEW2EM?U-A7GC`L>4,RA>94J17RL\C MP6U"''DIN%]D9T,7ZV%>IY#>D@`ODB./1[A7#_,Z[EW;)Z_#MHLI=?KO:D\DOV]^T'IHPI@6U<*4WG9OB+9$;@9`P92A@VV M`K'A%?I/E.VVK$S_8"\D#_>G7/V1-+#0U\W1>!6E:&J34=+\<.OK89XWW/-7 M\YN%>[W>R^Q\MIQKF8TT%$<7K`?KL*>/"\9$*6^U#V\B^1;7>9J+#5?6/C6P MN6O%9V3P^!]02P$"'@,4````"``@,%9!B/UY\/X:``"YR@``$0`8```````! M````I($`````<&AA`L``00E#@`` M!#D!``!02P$"'@,4````"``@,%9!6^L/Q]X#``#4'@``%0`8```````!```` MI(%)&P``<&AA&UL550%``-<&850=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`(#!606S;TM!:"@``L9H``!4`&````````0`` M`*2!=A\``'!H87(M,C`Q,C`X,S%?9&5F+GAM;%54!0`#7!F%4'5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`"`P5D'.1__DMQL``,$A`0`5`!@```````$` M``"D@1\J``!P:&%R+3(P,3(P.#,Q7VQA8BYX;6Q55`4``UP9A5!U>`L``00E M#@``!#D!``!02P$"'@,4````"``@,%9!+#/1C]D-``#PTP``%0`8```````! M````I($E1@``<&AA&UL550%``-<&850=7@+``$$ M)0X```0Y`0``4$L!`AX#%`````@`(#!60?M35WPR!P``9C@``!$`&``````` M`0```*2!350``'!H87(M,C`Q,C`X,S$N>'-D550%``-<&850=7@+``$$)0X` <``0Y`0``4$L%!@`````&``8`&@(``,I;```````` ` end XML 31 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Statements of Cash Flows (USD $)
6 Months Ended 19 Months Ended
Aug. 31, 2012
Aug. 31, 2011
Aug. 31, 2012
Operating Activities      
Net income (loss) for the period $ 10,957 $ (39,087) $ (79,740)
Adjustments to reconcile net loss to cash used in operating activities      
Gain on forgiveness of liabilities (39,500) 0 (39,500)
Changes in operating assets and liabilities:      
Accounts payable and accrued liabilities (9,004) 12,382 46,468
Expenses paid by related party 30,000 0 34,817
Net Cash Used In Operating Activities (7,547) (26,705) (37,955)
Financing Activities      
Proceeds from issuance of shares 12,551 0 25,271
Proceeds from related party 700 21,826 30,774
Repayments to related party (18,086) 0 (18,086)
Net Cash Provided by (Used in) Financing Activities (4,835) 21,826 37,959
Increase (Decrease) in Cash (12,382) (4,879) 4
Cash Beginning of Period 12,386 9,000 0
Cash End of Period 4 4,121 4
Supplemental Disclosures      
Interest paid 0 0 0
Income tax paid $ 0 $ 0 $ 0
XML 32 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Gain on Forgiveness of Debt
6 Months Ended
Aug. 31, 2012
Gain on Forgiveness of Debt  
Gain on Forgiveness of Debt

5.     Gain on Forgiveness of Debt

 

On August 31, 2012, the Company settled outstanding professional fees of $69,500 for $30,000 of debt that was personally assumed by the President and CEO of the Company.

XML 33 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 9 79 1 false 0 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Condensed Balance Sheets Sheet http://www.pharmainvestingnews.com/20120831/role/idr_CondensedBalanceSheets Condensed Balance Sheets false false R3.htm 000030 - Statement - Condensed Balance Sheets Parentheticals Sheet http://www.pharmainvestingnews.com/20120831/role/idr_CondensedBalanceSheetsParentheticals Condensed Balance Sheets Parentheticals false false R4.htm 000040 - Statement - Condensed Statements of Operations Sheet http://www.pharmainvestingnews.com/20120831/role/idr_CondensedStatementsOfOperations Condensed Statements of Operations false false R5.htm 000050 - Statement - Condensed Statements of Cash Flows Sheet http://www.pharmainvestingnews.com/20120831/role/idr_CondensedStatementsOfCashFlows Condensed Statements of Cash Flows false false R6.htm 000060 - Disclosure - Nature of Operations and Continuance of Business Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureNatureOfOperationsAndContinuanceOfBusiness Nature of Operations and Continuance of Business false false R7.htm 000070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R8.htm 000080 - Disclosure - Related Party Transactions Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureRelatedPartyTransactions Related Party Transactions false false R9.htm 000090 - Disclosure - Common Stock Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureCommonStock Common Stock false false R10.htm 000100 - Disclosure - Gain on Forgiveness of Debt Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureGainOnForgivenessOfDebt Gain on Forgiveness of Debt false false R11.htm 000110 - Disclosure - Subsequent Events Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureSubsequentEvents Subsequent Events false false R12.htm 000120 - Disclosure - Accounting Policies (POLICIES) Sheet http://www.pharmainvestingnews.com/20120831/role/idr_DisclosureAccountingPoliciesPOLICIES Accounting Policies (POLICIES) false false R13.htm 000130 - Statement - Going Concern (DETAILS) Sheet http://www.pharmainvestingnews.com/20120831/role/idr_GoingConcernDETAILS Going Concern (DETAILS) false false R14.htm 000140 - Statement - Related Party advances (DETAILS) Sheet http://www.pharmainvestingnews.com/20120831/role/idr_RelatedPartyAdvancesDETAILS Related Party advances (DETAILS) false false R15.htm 000150 - Statement - Related party notes (DETAILS) Notes http://www.pharmainvestingnews.com/20120831/role/idr_RelatedPartyNotesDETAILS Related party notes (DETAILS) false false R16.htm 000160 - Statement - Common Stock (DETAILS) Sheet http://www.pharmainvestingnews.com/20120831/role/idr_CommonStockDETAILS Common Stock (DETAILS) false false R17.htm 000170 - Statement - Forgiveness of Debt (DETAILS) Sheet http://www.pharmainvestingnews.com/20120831/role/idr_ForgivenessOfDebtDETAILS Forgiveness of Debt (DETAILS) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Condensed Balance Sheets Process Flow-Through: 000030 - Statement - Condensed Balance Sheets Parentheticals Process Flow-Through: 000040 - Statement - Condensed Statements of Operations Process Flow-Through: 000050 - Statement - Condensed Statements of Cash Flows Process Flow-Through: 000130 - Statement - Going Concern (DETAILS) Process Flow-Through: 000140 - Statement - Related Party advances (DETAILS) Process Flow-Through: 000150 - Statement - Related party notes (DETAILS) Process Flow-Through: 000160 - Statement - Common Stock (DETAILS) Process Flow-Through: 000170 - Statement - Forgiveness of Debt (DETAILS) phar-20120831.xml phar-20120831.xsd phar-20120831_cal.xml phar-20120831_def.xml phar-20120831_lab.xml phar-20120831_pre.xml true true